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Pseudomonas aeruginosa is a gram-negative bacterium that causes infections in immune 
compromised patients. There have been an increasing number of multi-drug resistant P. 
aeruginosa infections which is leading to the need to develop new targets for antibiotics. A 
potential new target is to disrupt iron homeostasis by disrupting the function of the iron storage 
protein, bacterioferritin B (BfrB). The structure and function of BfrB has been passionately 
studied in our lab, which has led to new understanding of iron uptake and iron release from BfrB. 
Iron mobilization from BfrB requires binding from the bacterioferritin-associated ferredoxin 
(Bfd), a process that our lab has demonstrated in vitro using X-ray crystallography, and binding 
studies. These studies also allowed the lab to determine the key residues in both proteins that 
stabilize the BfrB:Bfd complex.  
In my work, we have taken the insights from the in vitro studies and applied them to 
investigate the consequences of blocking the BfrB:Bfd interaction in P. aeruginosa cells. We 
first show that iron is essential to bacterial growth by testing the effects of an iron sequestering 
polymer developed in collaboration with Prof. Cory Berkland’s lab at the University of Kansas. 
The iron-sequestering polymer is capable of delaying bacterial growth and increasing the 
sensitivity of wild type (wt) P. aeruginosa to the antibiotics ciprofloxacin and gentamicin.  
I then studied cell growth and iron handling in response to mutating the bfrB gene (ΔbfrB), the 
bfd gene (Δbfd), or introducing a double mutation (E81A/L68A) in the bfrB gene in the 
chromosome of P. aeruginosa. From our previous in vitro studies, we predicted that E81/L68A 




through these studies that BfrB and the BfrB:Bfd interaction are essential for iron homeostasis in 
P. aeruginosa.  
The structural dynamics of BfrB have also been analyzed. We show that by mutating 
residues in the B-pores of the protein, we affect the function of the relatively distant ferroxidase 
center, which in turn inhibits iron oxidation and uptake. We show that concerted motions linking 
the pores and the catalytic center are essential for the function of BfrB.  
Lastly, our lab is engaged in developing compounds for blocking the BfrB:Bfd 
interaction. I have developed assays to show the effect of these compounds on cell growth and 
survival, and demonstrated that the compounds being developed in the lab boost the killing 





 I would first like to thank my advisor Dr. Mario Rivera.  You taught me the importance 
of details whether it was during experiments or presenting data.  I never stopped learning and 
was always being challenged as a student in your lab.  I hope in my future career I will have your 
enthusiasm for research and the desire to always want to know what’s new. 
 Thank you to my chemistry undergraduate professors at Wagner College. Without your 
help and guidance I would have never chosen to major in chemistry or continued my education at 
a higher level. 
 Thank you to all the past and present Rivera lab members.  I appreciate all your help and 
enjoyed working beside you.        
 I am very grateful for the support of my family.  Mom, Dad, and Sarah you were always 
willing to listen to the good and the bad.  I’m thankful for your diligent prayers and thoughts. 
You helped me push through to the very end when I had to jump over the highest hurdle.  Sarah 
and Lee, thank you for giving me adorable nieces.   They always bring joy and a smile to my 
face.   
 Thank you to all the friends I made in the graduate program.  Going through graduate 
school is not possible unless you have fellow students to vent and dance your problems away. 
 Thank you to the Betty and Zontal family. I will cherish the times I was able to escape 
from the lab and throw a Frisbee with some of the most extraordinary people I have ever met in 




Table of Contents 
The Role of Iron Storage Proteins in Pseudomonas aeruginosa Bacterial Iron Homeostasis i 
The Role of Iron Storage Proteins in Pseudomonas aeruginosa Bacterial Iron Homeostasis ii 
Abstract iii 
Acknowledgements v 
Table of Contents vi 
Table of Figures ix 
CHAPTER 1 : INTRODUCTION 1 
Iron is Essential for Growth 1 
Pseudomonas aeruginosa as a model bacterial organism 2 
Iron Acquisition 3 
FUR 10 
Iron Storage 10 
DPS 11 
Mammalian Ferritin 12 
Bacterial Ferritins and Bacterioferritin 13 
Targeting Iron for Antimicrobials 19 
Research Problem and Rationale 20 
References 22 
CHAPTER 2 : IRON SEQUESTRATION IN POLYMERS HAS 




Bacterial Strains and Growth Conditions 28 
Bacterial Growth Using PAI-DHBA-Treated Media 29 
Bacterial Growth in the Presence of PAI-DHBA 30 
Bacterial Growth in the Presence of PAI-DHBA Compared to Traditional Iron Chelating Agents
 30 
PAI-DHBA as an Adjuvant to Conventional Antibiotics 30 
Results 31 
PAI-DHBA is Specific to Iron in the Media 31 




PAI-DHBA is a More Potent Inhibitor of Bacterial Growth than Traditional Iron Chelators 36 
Adjuvant Effect of Iron-Sequestering Polymer on the Antimicrobial Activity of Ciprofloxacin and 
Gentamicin against P. aeruginosa 38 
Adjuvant Effect of G25 and Gentamicin 40 
Adjuvant Effect of G25 and Ciprofloxacin during Stationary Phase 42 
Discussion 43 
References 46 
CHAPTER 3 :  IRON MOBILIZATION FROM BFRB IS ESSENTIAL FOR 
IRON HOMEOSTASIS IN P. AERUGINOSA 48 
Introduction 48 
Experimental 53 
Bacterial strains, media and growth conditions 53 
Growth Curves 54 
Imaging Iron Storage in Bacterioferritin 54 
Growth Curves in Low Iron Media 55 
Pyoverdine Release 55 
Total Iron Analysis 56 
Iron Analysis in Spent Media 57 
EPR of Free Intracellular Iron 58 
Results 58 
BfrB is the Primary Iron Storage Protein in P. aeruginosa PA01 58 
Δbfd and bfrB* Mutants have Iron “stuck” in BfrB 61 
Δbfd and bfrB* Mutants Release Greater Amounts of Pyoverdine 62 
Mutants have Lower Levels of Free Intracellular Iron 67 
Discussion 71 
References 74 
CHAPTER 4 : DYNAMIC MOTIONS IN BACTERIOFERRITIN ARE 
NECESSARY FOR FERROXIDASE ACTIVITY 76 
Introduction 76 
Experimental Procedures 80 
Site-directed Mutagenesis and Protein Expression 80 
Iron Mineralization Assay 81 
Crystallization and Data Collection 82 
Structure Solution and Refinement 82 





D34F X-ray Crystal Structure 86 
Changes to B-Pores 89 
Ferroxidase Activity 90 
Iron Oxidation and Uptake 92 
Molecular Simulations 92 
Discussion 96 
References 97 
CHAPTER 5 : INHIBITORS OF THE BFRB-BFD INTERACTION 
INCREASE SUSCEPTIBILITY TO ANTIBIOTICS 99 
Introduction 99 
Experimental 102 
Bacterial Strains and Media 102 
Killing Assays 102 
Antibiotic and Compound Stock Solutions 103 
Growth Curves with Compound Only 103 
Growth Curves with Cipro and Compound 104 
Results 104 
Compound FC996 104 
Compound BN-XVI-069 106 







Table of Figures 
Figure 1-1: Haber-Weiss reactions cycle, in which iron catalyzes the formation of 
the highly toxic hydroxyl radical. 2 
Figure 1-2:  Structure of pyoverdine from P.aeruginosa without iron [16].  Chr is the 
chromophore of the structure which fluoresces unless bound to Fe
3+
. 6 
Figure 1-3: (A) The pyoverdine OM receptor, FpvA.  In light green is the beta-
barrel found in the OM.  In dark green is the plug and in red is the signaling 
domain.  (B) In orange is the ferri- siderophore complex binding to FpvA [16]. 7 
Figure 1-4:  A schematic of iron uptake pathways that supply iron to P.aeruginosa. 
The scheme shows the uptake pathways of iron through the release of 
siderophores pyoverdine and pyochelin, and their membrane receptors FpvA 
and FptA to bring in the ferri-siderophore complex. At the bottom of the 
diagram is the intake of ferrous iron through Feo, and the heme receptor 
proteins to bring heme into the cytoplasm.  The iron is shown to go to the 
intracellular iron pool and is then distributed to iron-utilizing proteins, iron 
storage proteins like bacterioferritin, and also to FUR, the  master ferric 
uptake regulator [20]. 9 
Figure 1-5:  Crystal structure of E.coli DPS (PDB 1L8I).  Each subunit is shown in 
an alternating color.  The 12 subunit structure forms an assembly with a hollow 
interior that can hold approximately 500 iron atoms. 12 
Figure 1-6:  X-ray crystal structure of horse spleen apoferritin (PDB 4V1W) [32].  
Each subunit is shown in an alternating color. 13 
Figure 1-7:  (A) X-ray crystal structure of E.coli ferritin (PDB 1EUM) 24-mer 
structure viewed along the 4-fold axis of symmetry [35]. Each individual 
subunit has been given a different color.  (B) The X-ray crystal structure of P. 
aeruginosa bacterioferritin (PDB 3IS8) 24-mer structure viewed along the 4-
fold axis of symmetry; the heme molecules (red) are located in between 2 
subunits [36]. 15 
Figure 1-8: X-ray crystal structure of the BfrB-Bfd complex from P. aeruginosa 
(PDB 4E6K) [39].  The BfrB protein is gray with the heme molecules being 
shown in red.  Located above each of the heme molecules is Bfd, shown in cyan, 
with its [2Fe-2S] cluster in orange and yellow. 17 
Figure 1-9:  Schematic of electron transfer from NADPH to the ferredoxin 
reductase (FPR) to Bfd [40].  The electron from Bfd passes through the heme in 








Figure 1-10: Key residues of the BfrB-Bfd interaction. BfrB is shown in grey and 
green and Bfd is in cyan.  The essential BfrB residues for Bfd binding are the 
glutamate 85, glutamate 81 and leucine 68.  Glutamate 81 and leucine 68 
provide a cleft where tyrosine 2 from Bfd can be inserted [40]. 18 
Figure 2-1:  Synthesis of the cross-linked PAI-DHBA iron sequestering polymer [9]. 27 
Figure 2-2:  (A) The iron stability constant (log scale) of the PAI-DHBA polymers 
was determined using a ligand competition assay.  The chelation of iron by 
PAI-DHBA in water was competed with the water soluble iron chelator, EDTA.  
(B) The iron sequestration capacities (mg Fe/g PAI-DHBA) were determined 
theoretically in black squares and experimentally in gray triangles. The PAI-
DHBA polymers were incubated in the presence of a FeCl3 solution for a week 
and the remaining Fe was determined.  (C)  The absorbed metals (mmol 
metal/g PAI-DHBA) were used to determine the selectivity of the PAI-DHBA 
polymers. These studies were completed by Jian Qian [9]. 32 
Figure 2-3: Metal selectivity study for PAI-DHBA polymer in M63 media.  One mL 
of media was incubated with 20 mg of G25.  This shows the polymer is selective 
to iron and does not sequester other important metals in the M63 media; 
therefore the effect on growth is specific to iron sequestration and not 
magnesium. 33 
Figure 2-4: Growth curve in the presence of G25. (A) M63 was treated with 1 
mg/mL (open circle), 10 mg/mL (filled triangle), 20 mg/mL (open triangle), or 
untreated (filled circle).  G25 slows the rate of growth compared to untreated 
cultures, and results in a lower cell count after 10 h of incubation with 1 
mg/mL. At 20 mg/mL of G25, the bacteria are unable to grow and cell death 
occurs.  (B) Treating M63 with polymer only, G0 (filled triangle), does cause a 
delay in bacterial growth.  When the media does not have iron added (open 
circle) there is a slight delay in growth and the final log CFU/mL does not reach 
the same cell count as the untreated (filled circle).  With the addition of 20 
mg/mL G25 (open triangle), the cells are unable to survive and cell death 
occurs. 35 
Figure 2-5: The effect of cell growth after 12 h in the presence of different 
concentrations (0, 1, 5, 10, 15, and 20 mg/mL) of G25.  Cultures were grown in 
24 well plates and the log CFU/mL was determined after 12 h of incubation. 
The addition of 20 mg/mL G25 had the greatest effect on bacterial growth. 36 
Figure 2-6: The growth of P. aeruginosa in the presence of 20 mg/mL G25 compared 
to 500 µM EDTA. G25 is capable of delaying growth and causes cell death.  
EDTA causes a slight delay after 6 h of culture, but is unable to prevent the 
bacteria from recovering and continuing to grow. 38 
Figure 2-7: (A) 20 mg/mL of G25 was added immediately after inoculation and then 




collected after 6, 7, and 9 h of incubating to determine cell survival after 
treatment. (B) 20 mg/mL of G25 and Cipro were added together or individually 
after incubating cultures for 5 h. (C) The polymer only (G0) was added 
immediately to the culture after inoculation and Cipro was added after 5 h of 
incubating. 40 
Figure 2-8: Survival of P. aeruginosa during log phase when treated with G25 
and/or Gent. (A) 20 mg/mL of G25 was added immediately after inoculation 
while 24 µg/mL of gentamycin was added after incubating the culture with or 
without G25 for 5 h.  Samples were collected after 6, 7, and 9 h of incubation to 
determine cell count by CFU/mL.  There were about 2 logs of increased killing 
with Gent and polymer compared to the polymer only and a difference of 4 logs 
of Gent and polymer compared to Gent only. (B) Gentamicin (24 µg/mL) and 
G25 (20 mg/mL) was added after 5 hours and samples were collected after 6, 7, 
and 9 h to determine cell count.  The final log CFU/mL was about 1.5 logs lower 
with Gent and G25 compared treatment of Gent or G25 only. 41 
Figure 2-9: Survival of P. aeruginosa during stationary phase when treated with 
G25 and/or Cipro. (A) The culture was inoculated and 20 mg/mL of G25 was 
added immediately.  The cultures were grown for 12 h to reach stationary 
phase and then treated with 1 µg/mL of Cipro.  The effect of the polymer in 
combination with Cipro increased the amount of killing by 1.5-2 logs killing 
compared to Cipro only or G25 only. (B) The addition of the polymer only, 
Cipro(-) and G25(+), after 12 h did not have a very significant decrease 
compared to Cipro(+) and G25(+) which saw about 2 logs more killing after 24 
h than Cipro(+) and G25(-). 43 
Figure 3-1: Electron path from the [2Fe-2S] cluster in Bfd to reduce Fe
3+
 in the core 
of BfrB. BfrB is shown in grey and Bfd is the faded cyan. Electrons travel from 
the [2Fe-2S] cluster of Bfd to the heme and then to the Fe
3+





is released outside of BfrB [17]. 51 
Figure 3-2: BfrB:Bfd interaction site.  The BfrB surface is shown in green and grey, 
Bfd residues are in cyan. Key residues from BfrB that interact with Bfd include 
E85, E81, L68, and N70. The oxygen atoms in E85 and E81 interact with M1 
from Bfd and there is a cleft between E81 and L68 that allows for Y2 from Bfd 
to anchor at the BfrB surface [17]. 52 
Figure 3-3: Iron storage in BfrB.  (A) The recombinant (Rec.) mineralized BfrB and 
FtnA proteins were used as standards in the native PAGE gels and stained with 
the iron specific, Ferene stain.  Note that the native gel can resolve FtnA and 
BfrB.  The bands obtained from separating lysates of wt P. aeruginosa cells 
indicate that iron is accumulated in BfrB during log phase and in early 
stationary phase. Cell growth is depicted by the growth curve shown in (B).  
Note that lysates of the ΔbfrB mutant show that there is no accumulation of 




aeruginosa. The plot in (C) shows the rate at which iron is taken by wt P. 
aeruginosa cells. 60 
Figure 3-4:  Growth curve and iron storage of wt and mutants. (A) When the cells 
are grown in iron sufficient media (> 5 μM), the wt and mutant cells grow at 
the same rate and to similar cell density. (B) Native PAGE gels showing that 
iron is stored in BfrB in all strains. Although the iron concentration in the 
media at the start of the experiment is the same for all strains, the wt cells need 
to mobilize iron stored in BfrB after 24 h of culture, whereas iron stored in 
BfrB of the Δbfd and bfrB* mutants appears to be “stuck”.  These observations 
indicated that without Bfd, or the ability of Bfd to bind to BfrB (bfrB*), iron is 
irreversibly stuck in BfrB.  The recombinant protein BfrB E81A is used for the 
standard for the bfrB* native gel. 62 
Figure 3-5:  The release of Pvd can be seen by shining UV-light on colonies plated 
on PIA.  (A) The wt strain releases some Pvd, but the Δbfd and bfrB* mutants 
release a much greater amount of Pvd, as seen by the fluorescent intensity 
surrounding the bacterial colonies.  (B)  The Δbfd and bfrB* mutants were 
complemented with the bfd and bfrB genes, respectively (ΔbfdminiTn7lacZbfd 
and bfrB*miniTn7lacZbfrB), which causes secretion of Pvd at levels lower or 
comparable to those seen with the wt strain. 65 
Figure 3-6:  Iron left in spent media and the release of Pvd in cultures of wt and 
mutant P. aeruginosa strains.  (A)  The iron left in the spent media was 
measured overtime for all strains.  ΔbfrB initially utilizes iron at a slower rate 
than the other strains, but has undetectable levels of iron at 48 h. The wt strain 
takes iron at a relatively fast rate through the log phase of growth and at a 
much slower rate during stationary phase, leaving behind around 2 µM in the 
media.  The Δbfd and bfrB* strains take iron at a fast rate through log and 
stationary phases until the levels of iron become undetectable at 24 h. (B) The 
release of Pvd can be measured by its fluorescent intensity.  The levels of Pvd 
were normalized for each strain by the cell count in log CFU/mL.  Δbfd and 
bfrB* begin to release Pvd earlier and at a fast rate after 24 h, compared to the 
slow and small amount of Pvd release by wt and ΔbfrB.  The release of Pvd 
correlates to the same time iron begins to be undetectable for Δbfd and bfrB*. 66 
Figure 3-7 Levels of total intracellular iron measurements and free intracellular 
iron at 12 and 24 h. (A) The total iron in the cells at 12 and 24 h is similar for 
wt, Δbfd and bfrB*.  ΔbfrB is lower at both time points. (B) Levels of free 
intracellular iron at 12 and 24 h. The free intracellular iron levels at 12 h are 
similar in wt and ΔbfrB but lower in Δbfd and bfrB*.  At 24 h the levels of free 
intracellular iron relative to wt are lower in the ΔbfrB mutant and even lower 
in the Δbfd and bfrB* cells. 69 
Figure 3-8:  The wt strain has a growth advantage when iron stored in BfrB can be 




transferred to iron-deplete media. The wt cells, which can utilize iron stored in 
BfrB, grow faster and reach a higher cell density compared to the Δbfd and 
bfrB* mutants, which are unable to utilize iron stored in BfrB. (B) Strains were 
grown in 8 µM Fe media for 24 h, so the wt cells had already mobilized the iron 
stored in BfrB. Unable to have access to iron reserves, the wt cells grow at a 
similar rate as the mutants in iron deplete media, which cannot access their 
iron stored in BfrB. 70 
Figure 4-1:  Structure of BfrB: (A) Subunit dimer and associated heme.  Each 
subunit is made up of a 4-helix bundle (helices A-D), a perpendicular short 
helix (E), and a loop connecting the B and C helices (green).  (B) Cross sectional 
view of the full 24-mer structure of BfrB that shows the inside cavity where 
mineral Fe
3+
 is stored; the heme is highlighted in green.  (C)  The residues that 
make up the ferroxidase center are shown in grey when no iron is present and 
in green when iron is located in the center.  H130 is adopts two conformations, 
iron bound and iron free, when iron is present. 77 
Figure 4-2:  (A) The 3 colored helices are highlighted to show one of the eight 3-fold 
pores.  (B)  The colored helices make up one of the 4-fold pores.  Four B-pores 
(circled) surround each of the 4-fold pores [6]. 79 
Figure 4-3: (A) Zoomed-in view of a 4-fold pore and a potassium ion (purple sphere) 
coordinated by the residues N148 and Q151.  (B) Zoomed view of a B-pore with 
a sodium ion (yellow sphere) coordinated by the residues D34, D132, and T136 
[6]. 79 
Figure 4-4:  Zoomed-in view of 4-fold pore in (A) wt and (B) D34F BfrB. Top: view 
of a 4-fold pore from the interior cavity. Bottom: cross-sectional view.  Iron 
atoms are orange spheres, water molecules are yellow spheres, sodium ion is a 
purple sphere, nitrogen atoms are shown in blue, and oxygen atoms in red [6]. 87 
Figure 4-5: View of the 3-fold pore in wt and D34F BfrB.  The top row is a cross-
sectional view of a 3-fold pore in the as-isolated structures.  The middle row is 
the same view as the top view but in Fe-soaked crystals.  The bottom row shows 
a 3-fold pore viewed from the interior cavity in Fe-soaked crystals.  Fe atoms 
are the orange spheres, water molecules are yellow spheres, sulfur atom are 
green, oxygen atoms are red and nitrogen atoms are blue [6]. 88 
Figure 4-6:  Zoomed-in view of the B-fold pore in wt and D34F BfrB.  The top row 
shows a view from the exterior of the protein.  The bottom row is a cross 
sectional view with the grey subunit seen in the top row removed.  The water 
molecules are yellow spheres, the iron ion is shown as a magenta sphere, oxygen 
atoms are red, and nitrogen atoms are blue [6]. 90 
Figure 4-7:  View of the ferroxidase center, as-isolated (grey) and Fe-soaked (green). 
(A) In the WT structure of as-isolated protein the side chain of H130 is rotated 




is observed in the gate open and gate closed conformations, which allow for the 
oxidized iron to be taken into the interior of the BfrB cavity.  (B) The structure 
of the D34F mutant shows that even after soaking in iron the H130 side chain 
does not coordinate iron and remains in the gate open conformation [6]. 91 
Figure 4-8: Molecular dynamics simulation of the fluctuations in wt and D34F BfrB.  
The top row shows plots of per-residue backbone RMSF in system E2 (red), 
E10 (green), E40 (blue), and per-residue crystallographic B-factors (black); 
helices A-E are indicated as boxes, and ferroxidase center residues are 
highlighted in green. The middle row depicts the per-residue backbone RMSF 
(systems E2) mapped onto a BfrB subunit, and the bottom row shows per-
residue backbone RMSF mapped on six subunits of the 24-mer assembly to 
illustrate relative flexibility at the 4-fold (blue stars), 3-fold (green stars), and 
B-pores (red stars).  Flexibility increases in the color scale from white to red [6].94 
Figure 4-9: Close up view of a B-pore taken during the MD simulations of (A) wt 
and (B) D34F BfrB. The three rotameric states of the F64 side chain in wt BfrB 
are depicted in white, yellow, and magenta sticks in (A), and the three 
rotameric states of D34 are indicated in the plot shown in (C). The rotameric 
exchange of D34 and F64 contributes to the breathing motions of the B-pores as 
well as ion traffic across B-pores in wt BfrB. In the D34F structure packing of 
F34 against L63 (spheres) likely contributes to the lower flexibility of B-pores in 
the mutant, due to  only one conformational rotamer of the F34 side chain (D) 
and only one conformation of the F64 side chain, wheat sticks in (B) [6]. 95 
Figure 5-1:  Bacterial survival 3 h after treatment with compound FC996.  1, 2, and 
3 mM compound was tested with 0.8 µg/mL of ciprofloxacin. After 3 hours of 
treatment, the bacterial survival treated with Cipro only (red) was 5%, with 1 
mM compound plus cipro (green) 1%, 2 mM compound + Cipro (blue) 0.5%, 
and 3 mM compound plus Cipro (purple) 0.1%. 106 
Figure 5-2:  Comparison of the adjuvant properties of isomeric compounds.  (A) 
Cultures were grown in M63 media to mid-log phase and treated with 800 µM 
compound 69 plus Cipro or 1 µg/mL Cipro only.  After 3 h of treatment with 
compound 69, which binds BfrB at the Bfd binding site, potentiates the killing 
activity of Cipro by 2 logs; treatment with 69 + Cipro (red bar), treatment with 
Cipro alone (black bar). (B) Compound 10 is an isomer of 69 but does not bind 
BfrB and therefore does not potentiate the killing activity of Cipro. 108 
Figure 5-3: Bacterial survival 4 h after treatment with 50 µg/mL Tobramycin and 
Compound 69. The effect caused by the compound is dose dependent and 
increases killing in combination with Tobramycin. The treatment with 
Tobramycin only (black bar) resulted in 5% survival, Tobramycin + 200 µM 69 
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Figure 5-7:  Growth curves of PA14 in the presence of compound 57 only. As the 
concentration of the compound increases, there is a slight delay in the log phase 
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Chapter 1 : Introduction 
Iron is Essential for Growth 
Iron is essential for most species including mammals and bacterial pathogens.  Fe can be 
used as a cofactor and a prosthetic group in essential enzymes that are involved in many cellular 




, each of 
which can have high or low spin states [2].  These properties of iron allow it to be incorporated 
into proteins as a biocatalyst or electron carrier [2].  For iron to be biologically active, it has to be 
incorporated into proteins as a mono- or binuclear species or in Fe-S clusters or in heme groups 
[2]. The incorporation of iron into proteins also allows for the redox potential of iron (range from 
-300 to +700 mV) to be controlled [2].  For optimal growth, most bacterial organisms require 
0.3-1.8 µM extracellular iron concentrations [3].  Iron is needed for metabolic processes such as 
replication, electron transport, TCA cycle, oxygen transport, nitrogen fixation, glycolysis, and 
DNA synthesis [1, 2].  Although iron is necessary, it has poor bioavailability and can induce 
oxidative stress to the cell. 
  Iron has poor bioavailability because Fe
3+ 
is almost insoluble under aerobic and neutral 
pH conditions, with solubility around 10
-18 
M [1].  Fe
2+
 is water soluble at neutral pH, but it can 
react with hydrogen peroxide (produced by cell metabolism) to form hydroxyl radicals and Fe
3+
 
through the Fenton reaction [4].  Fe
3+
 can be reduced back to Fe
2+
 by superoxide or other 
reducing agents in the cell, as illustrated in Figure 1-1 (Haber-Weiss cycle). This oxidative stress 




production of hydroxyl radicals causes protein denaturation and damage to DNA [1, 4].  To 
ensure sufficient iron concentrations for cellular processes, but prevent iron-induced toxicity, the 
free intracellular iron concentration is regulated around 10 µM [5].  
 
Figure 1-1: Haber-Weiss reactions cycle, in which iron catalyzes the formation of the highly 
toxic hydroxyl radical. 
Pseudomonas aeruginosa as a model bacterial organism 
Pseudomonas aeruginosa is an opportunistic pathogen that causes infections in immune 
compromised patients such as cystic fibrosis patients [6]. It has become very difficult to treat due 
to the increasing resistance of antibiotics.  The strains PA01 and PA14 are ideal to study in a 
laboratory setting and have had an abundance of research completed to study iron homeostasis 
[7].  We hope to use this information to develop potential therapeutics as well as further 
understand the complex system of iron regulation in the cell.  Background information on iron 






 Iron is not only used for essential functions in the cell, but it also affects the virulence of 
pathogens in the host.  Free iron is toxic to the host cells similar to bacteria.  The concentration 
of free intracellular iron in a mammalian host will be around 10
-9 
µM [3]. The host restricts the 
concentration of free iron by sequestering soluble iron in iron-binding proteins, such as 
transferrin, lactoferrin, or heme proteins [3].  Lactoferrin, an iron chelating glycoprotein, binds 
iron with extremely high affinity, and thus functions as a primary defense mechanism to restrict 
the growth of pathogens in a mammalian host. For example, lactoferrin has been shown to inhibit 
Pseudomonas aeruginosa biofilm formation which provides a potential therapeutic to combat P. 
aeruginosa biofilm formation in cystic fibrosis patients[1, 8]. In response, P. aeruginosa and 
other pathogens have developed multiple strategies to obtain iron in its host [8]. The pathogens 
obtain iron through pathways such as (i) sequestering heme from heme-binding proteins like 







its subsequent internalization via specific ferrous iron transporter (Feo), and degrading iron-
binding molecules like transferrin using enzymes [3]. 
Under anaerobic and typically iron-repressed conditions, Feo transcription will be 
induced.  In P. aeruginosa, ferrous iron is transported through the FeoABC system [9].  There 
are three proteins coded by the Feo operon, FeoA, FeoB, and FeoC.  FeoA, which is a small 9.3 
kDa cytosolic protein, is thought to activate FeoB [9].  FeoB is an 83 kDa protein with a soluble 
N-terminal domain and membrane integral C-terminal domain, and FeoC is a small 8.7 kDa 
cytosolic protein that is thought to regulate transcription of FeoB expression [9].  FeoB is most 
likely a Fe
2+ 




Helicobacter pylori and Campylobacter jejuni [9],  In P. aeruginosa, FeoB is essential for cell 
survival in the anaerobic environment of biofilms [9]. 
To obtain ferric iron, bacteria, as well as yeast, fungi, and plants, will produce high 
affinity extracellular ferric chelators called siderophores [10].  Siderophores are small molecules, 




[2].  There are over 
500 siderophores that have been characterized and they can be found in pathogenic and non-
pathogenic bacteria [2, 11].  In the case of gram-negative bacteria, secreted siderophores form a 
complex with Fe
3+
 (ferri-siderophore), which is recognized and internalized by an outer 
membrane (OM) receptor.  The complex is too large to go through porins which allow molecules 
such as glucose, phosphate, and amino acids to travel into the cell [10]. The ferri-siderophore 
will be transported to the inner membrane (IM) using the energy transducing TonB-ExbB-ExbD 
system, which is located in the IM and periplasm [12]. The complex will then interact with an 
ATP-binding cassette (ABC transporter), which will deliver it into the cytoplasm [2, 12].  The 
OM siderophore receptors are not present when there is sufficient iron, but are induced under 
iron starvation conditions.  The OM receptors have a high specificity towards the ferri-
siderophore complex. In the genome of P. aeruginosa, there are 35 TonB-dependent OM 
receptors which shows the importance of the capability of bringing in large amounts of iron 
bound siderophores [2]. 
P. aeruginosa secretes two siderophores, pyoverdine and pyochelin to chelate ferric iron 
and bring it into the cell [8].  Pyoverdine (Figure 1-2) is considered the main siderophore 










 [13].  The structure of pyoverdine is made up of a partially cyclized octapeptide attached 
to the 2,3-diamino-6,7-dihydroxyquinoline-based chromophore [14].  Ferric iron is chelated by 
the catechol group on the chromophore and the two hydroxyornithine side chains [14].  When 
pyoverdine is not bound by iron it exhibits green fluorescence and at pH 7.4 has an absorbance at 
405 nm, but when bound with Fe
3+ 
the fluorescence is quenched [15].  
To import the Fe
3+
-pyoverdine complex into the cell, it will bind to the outer membrane 
receptor FpvA (Figure 1-3A and 1-3B) and be actively transported into the cell by TonB-ExbB-
ExbD system [13, 16].  The FpvA is made up of 22 antiparallel β-strands to form a beta-barrel in 
the OM that forms a large pore about 35-40 Å in diameter [16].  In the pore there is a globular 
plug domain that prevents large molecules from crossing the membrane [16].  It undergoes a 
conformational change with the energy from the TonB system to allow the ferri-siderophore 
complex to pass through the receptor and enter the cell [16].  




During infections, pyoverdine 
competes with transferrin for iron [13]. Pyoverdine has been shown to be related to quorum 
sensing, and in bacteria like P. aeruginosa, it helps the colonization in low iron environments 
such as host tissue by competing with transferrin for iron [17].  It is also thought to be essential 
in the pathogen’s virulence, the development of mature biofilms, and to be competitive with 





Figure 1-2:  Structure of pyoverdine from P.aeruginosa without iron [16].  Chr is the 







Figure 1-3: (A) The pyoverdine OM receptor, FpvA.  In light green is the beta-barrel found in 
the OM.  In dark green is the plug and in red is the signaling domain.  (B) In orange is the ferri- 
siderophore complex binding to FpvA [16].  
Heme is the most abundant source of iron in mammals [2], so it is intuitive that bacteria 
would develop ways to acquire heme from the host to utilize the bound iron.  Bacteria are 
capable of using the heme, hemoglobin, or hemopexin-heme complex as sources of iron [2]. 
Pathogens are able to release heme from the proteins that bind it in the host by secreting 
hemolysins and proteases.  The released heme will either be captured by the bacteria or could 
possibly be taken back by the host protein [2].  There are two classes of heme acquisition in 




hemophores to capture and deliver the heme to cognate surface receptors [18].  The heme or 
heme-hemophore complexes will bind to OM receptors and then use the TonB-ExbB-ExbD 
system to transport the heme groups across the OM [2].  Hemophores that bind hemoglobin and 
hemopexin will also deliver heme to the OM receptors [2].  An ABC permease will transport the 
heme across the CM and be degraded by a heme oxygenase [2]. P. aeruginosa has 2 
interdependent heme uptake systems, the Phu, Pseudomonas heme utilization system and Has, 
heme assimilation system [18].  The Phu system encodes an OM receptor, PhuR, where heme is 
sequestered and brought into the cell by PhuT, the periplasmic transport system [18]. PhuT 
interacts with the PhuUV ABC transporter in the cytoplasm, where the heme is sequestered by 
PhuS.  PhuS transfers heme to heme oxygenase for subsequent break down of the heme into CO, 
biliverdin, and iron [19].  In P. aeruginosa, the hemophore, HasAp, acquires heme from the host 
and is brought to the OM receptor HasR [18, 19].  In the cytosol the heme is degraded by heme 
oxygenase into biliverdin, which releases iron and carbon monoxide [8, 18].  A full schematic of 





Figure 1-4:  A schematic of iron uptake pathways that supply iron to P.aeruginosa. The scheme 
shows the uptake pathways of iron through the release of siderophores pyoverdine and 
pyochelin, and their membrane receptors FpvA and FptA to bring in the ferri-siderophore 
complex. At the bottom of the diagram is the intake of ferrous iron through Feo, and the heme 
receptor proteins to bring heme into the cytoplasm.  The iron is shown to go to the intracellular 
iron pool and is then distributed to iron-utilizing proteins, iron storage proteins like 





To prevent oxidative stress and the buildup of free iron in the cell, iron concentration is 
tightly regulated with the aid of the ferric uptake regulator, FUR  [4].  FUR is a transcriptional 
repressor with Fe
2+ 
as its cofactor [4].  Fur can actively repress iron acquisition genes under iron- 
replete conditions [8].  When there is a high concentration of iron, Fe
2+ 
is bound to FUR, which 
binds to the promoter site of iron acquisition genes, preventing their transcription [4, 21].  FUR 
is also a positive regulator of genes such as iron storage proteins and iron-containing metabolic 
enzymes.  Under low iron conditions, Fe
2+
 will no longer bind to FUR which allows transcription 
of the small regulatory RNAs, PrrF1 and PrrF2 in P. aeruginosa, which will inhibit the 
expression of the iron storage proteins [4, 8, 21].  Iron acquisition genes directly regulated by 
FUR include the small Fe
3+
 chelating molecules, siderophores, like pyochelin and pyoverdine in 
P.aeruginosa, heme acquisition proteins, and the direct import of Fe
2+
.  In low iron conditions 
there is a decrease in expression of iron storage proteins and iron containing metabolic proteins 
[22].  This is essential for the bacteria to maintain enough iron in the cytoplasm iron pool for 
necessary functions [23]. 
Iron Storage 
The necessity to have iron for biological functions, but the potential for cell damage from 
iron has led organisms to evolve safe strategies to store iron, which utilize the iron storage 
proteins, ferritins.  Ferritins are large spherical proteins that store iron in their internal cavity as a 
ferric mineral [24].  Ferritins have been described as having the primary function of storing 




when there is low iron availability in the environment [24]. The potential of iron toxicity leads to 
the tight regulation of iron and the storage of excess iron in iron storage proteins [1, 25].  In P. 
aeruginosa and in other pathogens there are three types of ferritin-like molecules- the DNA 
binding protein (DPS), the classical bacterial ferritin (Ftn) and the bacterioferritin (Bfr) [26].   
DPS 
DPS are present in bacteria and archaea [26].  DPS has a different structure and function 
in the cell compared to the bacterial ferritins and the bacterioferritin. DPS is made of 12 subunits 
(Figure 1-5) and can accumulate up to 500 Fe atoms [27].  Iron is accumulated by oxidizing Fe 
(II) to Fe (III) at the ferroxidase center which is at the interface of adjacent subunits [26].  DPS in 
some bacteria such as E. coli have been shown to bind DNA and protect it from oxidative 
degradation [27].  Not all DPS have been shown to bind DNA such as in Listeria 
monocytogenes. In this bacteria, iron is stored in DPS and the primary function is suspected to be 





Figure 1-5:  Crystal structure of E.coli DPS (PDB 1L8I).  Each subunit is shown in an 
alternating color.  The 12 subunit structure forms an assembly with a hollow interior that can 
hold approximately 500 iron atoms. 
Mammalian Ferritin 
 Ferritins (Ftn) are found in eukaryotes as well as in bacteria [28].  The mammalian 
ferritins differ from the ferritins found in bacteria in that mammalian ferritins are assembled from 
two types of subunits, whereas bacterial ferritins are assembled from a single type of subunit 
[29].  The subunits that make mammalian ferritins are termed the heavy (H) and the light (L) 
chains, which assemble into a 24-mer structure (Figure 1-6).  There is only 55% sequence 
identity between the H and L chains, but the chains are mutually interchangeable to form the 24 
subunit structure [30]. The H chains are catalytically active because they contain the ferroxidase 
centers where Fe
2+
 is oxidized to Fe
3+




not harbor ferroxidase centers, but they have been shown to contain nucleation sites where iron 
can nucleate to form a mineral [31].  
 
Figure 1-6:  X-ray crystal structure of horse spleen apoferritin (PDB 4V1W) [32].  Each subunit 
is shown in an alternating color. 
Bacterial Ferritins and Bacterioferritin 
 Bacterial ferritins (Ftn) and Bacterioferritin (Bfr) are unique to bacteria. These proteins 
have similar 24-mer structures to the ferritins found in mammals but have significant subunit 
differences [33]. The structures of E.coli Ftn and P.aeruginosa Bfr can be seen in Figure 1-7A 
and 1-7B. They are both made from 24 identical subunits that assemble into a spherical, hollow 
cage that can hold approximately 4,500 iron atoms [31]. The structure and sizes of both types of 




120 Å, and a cavity with 80 Å diameter. The storage of the ferric mineral is possible by oxidizing 
ferrous ions at the ferroxidase centers.  Both Ftn and Bfr contain ferroxidase centers in every 
subunit, where the binding of ferrous iron to form a di-iron center takes place immediately prior 
to oxidation to the ferric iron and translocation into the cavity of the proteins [34]. The 
ferroxidase centers are located in the middle of each subunit, which is composed of a four-helix 
bundle [34].  Bfr are unique among ferritin-like molecules in that these proteins bind heme 
between 2 subunits [31].  Depending on the bacterial strain, the two proteins have been shown to 
either be a primary iron storage protein or be related to controlling oxidative stress.  For 
example, it was shown in E.coli that without the Ftn there was a 50% less total iron in the cell, 
and the growth rate of the mutant bacteria was reduced under low iron conditions. In 
comparison, in C. jejuni and H. pylori the Bfr mutants are more sensitive to redox stress [2]. The 
role of Bfr in Salmonella Typhimurium is essential for iron storage and full virulence, but Ftn 
does not contribute to storing large amounts of iron [28]. The function of iron stored in 
Salmonella Bfr contributed to lowering oxidative stress produced by hydroxyl radicals and 
reactive oxygen species, and it was also shown to be required for the iron-sulfur cluster aconitase 





Figure 1-7:  (A) X-ray crystal structure of E.coli ferritin (PDB 1EUM) 24-mer structure viewed 
along the 4-fold axis of symmetry [35]. Each individual subunit has been given a different color.  
(B) The X-ray crystal structure of P. aeruginosa bacterioferritin (PDB 3IS8) 24-mer structure 
viewed along the 4-fold axis of symmetry; the heme molecules (red) are located in between 2 
subunits [36]. 
 
In Pseudomonas aeruginosa both types of iron storage proteins, the bacterial ferritin 
(FtnA) and the bacterioferritin (BfrB) are present [37]. The functions of these two iron storage 
proteins remain enigmatic, although, as will be shown in this work, we now know that BfrB is 
the main iron storage protein in P. aeruginosa cells. Although FtnA and BfrB have a similar 
structure, they have less than 18% amino acid sequence homology [38].  Like a typical bacterial 




protein to coordinate a heme molecule in between two subunits; M52 is not present in FtnA [37]. 
This leads to a different process of iron mobilization from BfrB compared to FtnA [37].  
Adjacent to the bfrB gene is the bacterioferritin- associated ferredoxin (bfd) gene, which is also 
been conserved in other pathogens [39].  Bfd has been shown to be necessary for iron release 
from BfrB [39]. The crystal structure of the BfrB-Bfd (Figure 1-8) complex shows Bfd binding 
above the heme in BfrB.  This allows for the passing of electrons from Bfd into the core of BfrB 
to reduce the ferric mineral and be released as ferrous iron [39]. The scheme of how electrons are 
passed into the core of BfrB is seen in Figure 1-9.  The electrons are passed from NADPH to the 
ferredoxin reductase (FPR) to Bfd which then pass the electrons into the core of BfrB through 




 which can then be released to the cytosol. 
Further investigations in our laboratory determined the essential interactions between the 
Bfd and BfrB residues [40]. The essential residues in BfrB that promote binding of Bfd have 
been shown to be residues leucine 68, glutamate 81, and glutamate 85 (Figure 1-10) [40].  This 
was elucidated by making site directed mutations of these residues to alanine and performing 
binding studies using SPR and in vitro iron mobilization assays. The dissociation constant (Kd) 
of the BfrB:Bfd complex was determined to be 3.3 µM at pH 7.4 [40]. The mutations resulted in 
significantly higher Kd; 258 µM with E81A, 298.5 µM with L68A, and 590 µM with E85A [40].  
Importantly, introducing the double mutation E81A/L68A in BfrB resulted in complete 
abrogation of binding.  In the in vitro assays of iron mobilization from BfrB, this double mutant 
BfrB acted the same as the control with no Bfd present in the assay.  The E81A/L68A double 
mutant eliminated the Bfd interaction with BfrB, which inhibited the transfer of electrons from 




BfrB and this interaction is required for the release of iron from BfrB which led to the work that 
will be discussed in this Dissertation.   
 
Figure 1-8: X-ray crystal structure of the BfrB-Bfd complex from P. aeruginosa (PDB 4E6K) 
[39].  The BfrB protein is gray with the heme molecules being shown in red.  Located above 






Figure 1-9:  Schematic of electron transfer from NADPH to the ferredoxin reductase (FPR) to 







Figure 1-10: Key residues of the BfrB-Bfd interaction. BfrB is shown in grey and green and Bfd 
is in cyan.  The essential BfrB residues for Bfd binding are the glutamate 85, glutamate 81 and 





Targeting Iron for Antimicrobials 
There is a need for new antibiotic targets due to an increase in antibiotic resistance. To 
address this issue, one focus of research has been to explore the inhibition of iron uptake by the 
bacterial cell [41]. Iron is not only needed for important biological functions, but it is necessary 
for virulence [1].  In the mammalian host, the amount of free Fe is approximately 10
-18
 M to 
prevent acute and chronic infections [42]. Preventing iron uptake or disrupting iron homeostasis 
is probably valid target for new antibiotics because bacteria need iron to survive, but if not 
properly regulated, it could lead to oxidative stress. For example, small molecules have been 
developed to inhibit the production of siderophores secreted by Mycobacterium tuberculosis and 
Yersinia pestis [43]. By disrupting bacterial strategies to scavenge iron, it is thought that the 
growth will be inhibited. Also, mutant strains lacking the iron scavenging systems in Y. pestis 
were avirulent in mice and unable to grow in iron limiting media [43].  Researchers have 
attempted to inhibit iron scavenging systems, but most pathogens have multiple iron uptake 
pathways that cannot be targeted all at once [44]. Iron chelation therapy has also been tested, but 
some pathogens are capable of using the chelated iron complex to form secondary infections 
[44]. 
Tricking the bacteria to uptake other metals in place of iron has been suggested as an 
alternative method.  The transition metal gallium has been used in a ‘Trojan horse” strategy 
because Ga
3+
 has similar chemical properties as Fe
3+
, so the cell will uptake Ga and not release 
siderophores. Importantly, Ga
3+




so it is unable to perform the 




and to reduce iron uptake through the pvdS (siderophore) pathway. This eventually led to Ga 
replacing iron and affecting cellular function.   
Research Problem and Rationale 
Targeting bacterial iron homeostasis is a potentially valid target for developing novel 
antibiotics due to the potential toxicity caused to the bacterial cell by iron homeostasis 
dysregulation.  To target bacterial iron homeostasis it is necessary to understand how bacteria 
control iron storage and subsequent mobilization of stored iron into the cytosol of bacterial cells, 
so one may specifically target the protein’s function.  In P. aeruginosa there are three ferritin- 
like proteins, but only two (FtnA and BfrB) are considered to function as iron storage proteins.  
To disrupt iron homeostasis, it was necessary to determine where the iron was being stored, FtnA 
or BfrB.  In this dissertation, we describe results that show that BfrB is the primary iron storage 
protein in P. aeruginosa, as well as how we capitalized from the insights gained from our 
laboratory in vitro studies to design experiments aimed at probing the consequences of blocking 
the BfrB:Bfd interaction in P. aeruginosa cells. Results from these studies will be described and 
discussed in detail in Chapter 3. 
To understand how we might perturb the function of BfrB in P. aeruginosa cells, we 





, and how perturbation of dynamics in sites remote to the ferroxidase sites inhibits 
ferroxidase activity. We also studied the phenotypes of cells with deletions in the bfrB and bfd 
genes, as well as mutant cells where the bfrB gene carries the E81A/L68A double mutation in the 




response when the function of iron storage or release is disrupted, and strongly suggest that 
targeting bacterial iron homeostasis is a viable approach to develop anti-infectives.  We also 
demonstrated, in collaboration with the Berkland laboratory, that chelating iron available in the 
environment by irreversibly sequestering it in polymers severely weakens bacterial cells. The 
development of novel therapeutics by disrupting the BfrB:Bfd interaction has also been tested.  
The bacteria’s ability to uptake iron is probably a poor target due to the bacteria’s multiple 
mechanisms of obtaining iron. On the other hand, targeting bacterioferritin function may offer 
several advantages.  First, bacterioferritins are unique to bacteria, so small molecules developed 
to bind bacterioferritin would be specific to bacterioferritin and would not bind to the eukaryotic 
ferritin.  The BfrB-Bfd genes have been found in multiple pathogens, which provide the 
possibility of developing molecules with broad spectrum of action, which indicate that our 
approach, and what we learn from our investigations with P. aeruginosa, will likely be of 
widespread impact.  In addition, small molecules that affect iron homeostasis in P. aeruginosa 
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Chapter 2 : Iron sequestration in polymers has antimicrobial 
properties 
Introduction 
Pseudomonas aeruginosa is a gram-negative bacterium that causes infections in immune 
compromised patients, such as burn victims and cystic fibrosis patients [1].  Multidrug resistance 
has become a serious problem with P. aeruginosa infections because it has an unusual number of 
efflux pumps [2] and the ability to form biofilms.  The efflux pumps  are capable of exporting 
antimicrobial agents and the biofilm creates a barrier that protects the cells from taking in the 
antibiotics [1, 3].   
The formation of biofilms is greatly dependent on the presence of iron.  Iron 
concentration in the environment less than 1 µM or greater than 100 µM slows biofilm growth 
[1].  Iron is essential not only for biofilm growth, but it is an essential nutrient for cell growth 
and metabolism because it participates in a variety of cellular functions such as the tricarboxylic 
acid (TCA) cycle and DNA synthesis [4].  Since iron is essential for many primary functions, 
removing iron from the environment can weaken bacteria, and increase the susceptibility of 
bacteria to antibiotics [1, 5]. 
Some iron chelators have been tested in combination with current antibiotics that show 
increased killing. In one study, the FDA approved iron chelators, deferasirox and deferoxamine, 
were used in combination with the antibiotic Tobramycin to treat biofilms grown on cystic 




approximately 7 logs of increased killing in presence of the iron chelators [6].  In other studies, 
specific iron chelators do not enhance the efficacy of antibiotics.  For example, the study 
completed by Liu used the small iron chelators, 2,2-bipyridl (10 µg/mL), acetohydroxamic acid 
(80 µg/mL) and EDTA (5 µg/mL) in combination with ciprofloxacin which had similar survival 
to treatment with ciprofloxacin alone [7].  The chelators did have an effect on biofilm formation 
when they were tested in combination with an efflux pump inhibitor.  Except for EDTA which 
showed a decrease in biofilm formation; EDTA can cause the release of lipopolysaccharides 
from the cell wall which was thought to have helped promote the formation of biofilms [7].    
High affinity iron chelators that have been tested for antimicrobial activity have been 




 chelators, such as 
mycobactins and carboxymycobactins from Mycobacterium tuberculosis and yersiniabactin from 
Yersinia pestis [8].  In the study presented in this chapter, a polymer harboring the chelating 
moiety of the siderophore enterobactin was synthesized.  Developing polymers with iron 
chelating groups provides advantages relative to small molecular weight chelators. These 
polymers, in addition to having high binding affinity for Fe
3+
, also have large binding capacity 
and can sequester iron inside the polymeric structure, where it is not available to bacteria.  The 
polymer is a non-absorbable chelator which could be used as a topical treatment of bacterial 
infections such as P. aeruginosa infections on burns [9].  Cross-linked polymeric materials 
cannot be absorbed through skin which would reduce concerns about toxicity.  There may be a 
synergistic effect with iron sequestering materials and antibiotics which could reduce the 




The polymer was synthesized by cross-linking primary amine groups in polyallylamine 
(PAI) with N,N’-methylenebis(acrylamide) (MBA) and conjugating with 2,3-dihydroxybenzoic 
acid (DHBA) (Figure 2-1) [9].  The iron sequestering polymer (PAI-DHBA) was synthesized 
with different molar ratios of the cross-linker to the number of total amines.  The ratio of 
DHBA/amines was prepared to be 0, 5, 10, 15, 20, 25, 30, 35, and 40, which was designated as 
G0, G5, G10, etc.  The iron stability constant, iron sequestration capacity, and iron selectivity 
was tested with the PAI-DHBA with these different ratios and the PAI-DHBA, G25, was chosen 
to be used in the studies described in this chapter because it showed the highest selectivity with 
optimal iron-sequestering capacity and stability constant [9].  The growth of bacteria in the 
presence of G25 was found to be significantly slowed. In addition, some antibiotics were found 
to be more effective at killing P. aeruginosa when used in the presence of G25.      
 







Ciprofloxacin hydrochloride was purchased from MP Biomedicals, Inc. Gentamicin 
sulfate, sodium ethylene diamine tetraacetate (EDTA), agar, iron sulfate hepta-hydrate, glucose, 
potassium hydroxide, and casamino acids (BD Falcon) and potassium chloride (KCl) were 
purchased from Fisher Scientific. Potassium phosphate monobasic, potassium phosphate dibasic, 
magnesium sulfate, tryptophan, and citric acid were purchased from Sigma.  Luria broth media 
(LB, pH 7.1) was purchased from Teknova. N, N-bis (2-hydroxybenzyl) ethylenediamine-N, N-
diacetic acid (HBED) was purchased from Strem Chemicals, Inc. Sodium chloride (NaCl) was 
purchased from Acros Organics. Potassium dihydrogen phosphate (KH2Po4) and disodium 
hydrogen phosphate (Na2HPO4) were purchased from Santa Cruz Biotechnology, Inc. 
Bacterial Strains and Growth Conditions 
P. aeruginosa strain PA01 purchased from the University of Washington Genome 
Sciences was used in all studies. P. aeruginosa was grown in M63 minimal media, as modified 
by O’Toole and Kolter [10]. M63 media was prepared by dissolving 2 g/L KH2PO4, 13.6 g 
(NH4)2SO4, 3 µM FeSO4-7H2O and 1 mM MgSO4 per 1L water and autoclaving.  Then 2 g 
glucose, 5 g casamino acids, 0.25 g tryptophan, 4 g citric acid are added.  The pH was adjusted to 
7.0 with the addition of KOH and then filter sterilized. All glassware was acid washed by 





Bacterial Growth Using PAI-DHBA-Treated Media 
The iron-sequestering polymer PAI-DHBA (G25) was utilized in the following studies 
with P.aeruginosa. The polymer cPAI (G0), without the DHBA iron chelating moiety, or PAI-
DHBA (G25) powder was washed twice with phosphate buffer saline (PBS at pH 7.4) and once 
with deionized water, and then lyophilized.  A 50 mL aliquot of M63 media containing 1, 10, or 
20 mg/mL insoluble G25 was incubated for 20 min with shaking (230 rpm, 37 °C). In addition, 
50 mL of M63 media was also incubated with G0 (13.9 mg/mL) for 20 min to control for the 
absence of DHBA moieties in the polymer; 13.9 mg/mL G0 was used because this mass is 
equivalent to 20 mg of G25, which is composed of 13.9 mg of cPAI and 6.1 mg of DHBA. After 
incubation the polymer was removed from the media by centrifuging the 50 mL at 4000 rpm at 4 
°C for 15 min.  The supernatant was transferred to an acid washed 250 mL Erlenmeyer flask. 10 
mL of the supernatant was removed to measure the iron content using inductively coupled 
plasma optical emission spectrometry (ICP-OES).  Bacterial growth was also examined using 
M63 media without the addition of iron. 
Bacteria were grown from a single colony in 5 mL of LB overnight with shaking at 230 
rpm and 37 °C. The overnight inoculum was centrifuged for 12 min at 4000 rpm and 4 °C, and 
then resuspended in M63.  The resuspended cells were added to the 40 mL of polymer-treated or 
untreated media to give a starting OD600 = 0.01.  The cells were cultured with shaking at 230 rpm 
and 37 °C.  1-2 mL was sampled every hour to measure the OD600.  At 2, 4, 6, 8, 10 h of growth, 
100 µl was sampled and serially diluted in PBS. Ten, 10 µL drops of the dilutions were plated on 
LB agar and incubated at 37 °C for 18 h. The colony forming units/mL was determined by 




Bacterial Growth in the Presence of PAI-DHBA 
An overnight culture in LB was diluted in fresh LB to OD600 = 0.3. 10 µL of the diluted 
culture was added to 1 mL of M63 in a 24 well flat-bottomed plate to give a starting OD600 = 
0.003. 1, 5, 10, or 20 mg/mL of G25 was added to each well to compare the bacterial growth at 
different amounts of polymer.  The plate was wrapped with parafilm and incubated with shaking 
at 40 rpm, 37 °C for 12h. The entire culture was removed and serially diluted in PBS and plated 
on LB agar. The agar plates were incubated for 16-18 h at 37 °C.  Single colonies were 
enumerated to determine the CFU/ mL. 
Bacterial Growth in the Presence of PAI-DHBA Compared to Traditional 
Iron Chelating Agents  
The experiment was setup in 24 well plates as previously described.  20 mg of PAI-
DHBA or 208 mg of EDTA (500 µM) was added to the media immediately after inoculating 
with P. aeruginosa.  The CFU/mL was determined after 5, 6, and 12 h of incubation. 
PAI-DHBA as an Adjuvant to Conventional Antibiotics 
Ciprofloxacin (1 µg/mL) or gentamicin (24 µg/mL) was added to 24-well plate cultures 
after 5 h of growth.  G25 was added to M63 immediately after inoculation with P. aeruginosa or 
together with the antibiotics after 5 h of growth. At different time of incubation (5, 6, 7, and 9 h), 
the entire content of each well was serially diluted and plated on LB agar to determine CFU/mL. 
cPAI (G0) was also tested with ciprofloxacin by adding polymer immediately after inoculating 




Ciprofloxacin was also added to 1 mL cultures after 12 h of incubation in the 24 well 
plate. G25 (20 mg/mL) was added to media either immediately after inoculation or 
simultaneously with ciprofloxacin.  CFU/mL was determined at 12, 13, 14, 16, and 24 h of 
growth. 
Results 
PAI-DHBA is Specific to Iron in the Media 
To determine which DHBA/ amine ratio (G0 through G40) would be used for the 
susceptibility testing, the PAI-DHBA polymers were tested for their iron stability constant, iron 
sequestration capacity and the iron selectivity (Figures 2-2A, 2-2B, and 2-2C). The iron affinity 
constant was determined by a ligand competition assay with EDTA which has a log stability 
constant of 25.1.  Figure 2-2A shows that all polymers have at least 10
3
 times stronger iron 
affinity than EDTA[9].  In Figure 2-2B the iron sequestration capacity of the polymers shows the 
maximum iron adsorption by the polymers (mg Fe/g PAI-DHBA).  Theoretically, the iron 
sequestration was expected to continue to increase, but at G20, the experimental capacity begins 
to plateau.  This was explained by the possible increase of the polymer’s hydrophobicity due to 
DHBA moieties which limited the ability of iron to access the interior of the gel-particle [9].  It 
was essential to measure the specificity of iron compared to other metals in the media that could 
affect bacterial growth.  To measure the specificity, multiple metals including Fe, Ca, Cu, Mn, 
Ni, K, and Zn were put into solution at 0.4 mM, and the metal/polymer ratio was fixed at 0.2 
mmol per gram of polymer.  The polymer absorbed almost all the iron in each sample and very 




with optimal iron-sequestering capacity and stability constant.  It was then chosen for the testing 
of antimicrobial activity.  M63 media is prepared with the addition of two metals, magnesium 
and iron.  To ensure the G25 polymer was going to be specific towards iron, the total metals 
absorbed was analyzed.  The polymer was capable of sequestering all of the iron in M63 but only 
12% of Mg
2+
, as shown in Figure 2-3.  The swelling of the polymer most likely caused the Mg
2+
 
to be physically absorbed with water rather than be specifically chelated.  
 
Figure 2-2:  (A) The iron stability constant (log scale) of the PAI-DHBA polymers was 
determined using a ligand competition assay.  The chelation of iron by PAI-DHBA in water was 
competed with the water soluble iron chelator, EDTA.  (B) The iron sequestration capacities (mg 
Fe/g PAI-DHBA) were determined theoretically in black squares and experimentally in gray 
triangles. The PAI-DHBA polymers were incubated in the presence of a FeCl3 solution for a 
week and the remaining Fe was determined.  (C)  The absorbed metals (mmol metal/g PAI-
DHBA) were used to determine the selectivity of the PAI-DHBA polymers. These studies were 





Figure 2-3: Metal selectivity study for PAI-DHBA polymer in M63 media.  One mL of media 
was incubated with 20 mg of G25.  This shows the polymer is selective to iron and does not 
sequester other important metals in the M63 media; therefore the effect on growth is specific to 
iron sequestration and not magnesium. 
PAI-DHBA Treated Media Suppresses Bacterial Growth 
P. aeruginosa was grown in the presence of media that was treated with 0, 1, 10, and 20 
mg/mL of G25.  At 1 and 10 mg/mL G25 there was a delay in bacterial growth, but at 20 mg/mL 
there was cell death (Figure 2-4A).  The polymer at 20 mg/mL is capable of chelating all 




iron available to the cells in the culture, cells likely become iron deficient and cannot grow 
resulting with some cells dying.  
The treatment with (G0) which has no iron-chelating DHBA moieties exerted little 
difference to bacterial growth, similar to that seen with untreated control (Figure 2-4B).  When 
media was not supplemented with iron, there was a longer logarithmic phase and the cell count 
was about a log lower than the culture in iron-supplemented media after 10 h of incubation.  By 
completely depleting the culture of iron by the addition of 20 mg/mL of G25, the bacteria was 
unable to grow and led to cell death.  This shows that the effect on cell growth is due to the iron 
sequestration by the chelating moiety of G25 and not the polymer.  Polymers have been shown to 
have antibiotic properties, so it was necessary to verify it was not contributing to the killing of 





Figure 2-4: Growth curve in the presence of G25. (A) M63 was treated with 1 mg/mL (open 
circle), 10 mg/mL (filled triangle), 20 mg/mL (open triangle), or untreated (filled circle).  G25 
slows the rate of growth compared to untreated cultures, and results in a lower cell count after 10 
h of incubation with 1 mg/mL. At 20 mg/mL of G25, the bacteria are unable to grow and cell 
death occurs.  (B) Treating M63 with polymer only, G0 (filled triangle), does cause a delay in 
bacterial growth.  When the media does not have iron added (open circle) there is a slight delay 
in growth and the final log CFU/mL does not reach the same cell count as the untreated (filled 
circle).  With the addition of 20 mg/mL G25 (open triangle), the cells are unable to survive and 
cell death occurs. 
Treatment of the media with the polymer immediately after inoculation was also 
investigated.  Bacteria were inoculated into 1 mL of media in 24 well-plates, followed by 




was serially diluted and plated on PIA to determine the total cell count.  As the polymer 
concentration increased the cell count decreased, as seen in Figure 2-4. Because of these 
observations, subsequent experiments were carried out with 20 mg/mL of G25. 
 
Figure 2-5: The effect of cell growth after 12 h in the presence of different concentrations (0, 1, 
5, 10, 15, and 20 mg/mL) of G25.  Cultures were grown in 24 well plates and the log CFU/mL 
was determined after 12 h of incubation. The addition of 20 mg/mL G25 had the greatest effect 
on bacterial growth. 
PAI-DHBA is a More Potent Inhibitor of Bacterial Growth than Traditional 
Iron Chelators 
The PAI-DHBA polymer was compared to other traditional iron chelators to determine if 
it would have a higher efficacy to prevent or delay bacterial growth.  500 µM of EDTA, a well-




untreated culture and culture treated with 20 mg/mL G25.  In the presence of EDTA, there was a 
slight delay in growth after incubating for 5 and 6 h, but after 12 h of growth, the bacterial cell 
count was similar to that observed in the untreated culture.  In comparison, the culture treated 
with 20 mg/mL of G25 was significantly decreased in cell count at 5, 6, and 12 h, as seen in 
Figure 2-6.  The affinity of EDTA for Fe (III) at pH 7.0 is 10
25
 [12].  Pyoverdine, iron (III) 
siderophore, released from P. aeruginosa also has an affinity constant of 10
25
 [13].  P. 
aeruginosa may have produced pyoverdine when it sensed iron deprivation caused by EDTA. 
Because of the reversible binding of iron (III) to EDTA, the pyoverdine siderophore can 
gradually compete with EDTA and allow the cells to acquire iron.  In contrast, the polymer 
sequesters iron nearly irreversibly within its structure, where pyoverdine cannot access, thus 
preventing the siderophores from capturing the iron from the polymer and leading to the 





Figure 2-6: The growth of P. aeruginosa in the presence of 20 mg/mL G25 compared to 500 
µM EDTA. G25 is capable of delaying growth and causes cell death.  EDTA causes a slight 
delay after 6 h of culture, but is unable to prevent the bacteria from recovering and continuing to 
grow.  
Adjuvant Effect of Iron-Sequestering Polymer on the Antimicrobial Activity 
of Ciprofloxacin and Gentamicin against P. aeruginosa 
The addition of iron chelators to antibiotics has shown to increase the bactericidal effect 
of antibiotics [5, 14]. Common antibiotics used to treat P. aeruginosa infections belong to the 




ciprofloxacin, respectively [1].  To investigate the adjuvant effect of the polymer to antibiotics, 
the bacterial survival was tested in two types of conditions.  One condition consisted of culturing 
the bacteria in the presence of G25 (20 mg/mL) for 5 h, then adding the antibiotics (ciprofloxacin 
at 1 µg/mL or gentamicin at 24 µg/mL) and collecting samples of the cultures at 6, 7, and 9
 
h.  
The second condition allowed the bacterial culture to reach mid-log phase (approximately 5 h), 
then simultaneously add G25 and antibiotics. The cell counts were enumerated at 6, 7, and 9 h of 
culturing. The concentrations of the antibiotics were used from the reported MICs against P. 
aeruginosa [15].  
 In Figure 2-7A, the first set of bars show the growth of the bacteria untreated, labelled 
[G25(-)/Cipro(-)].  When Cipro only [G25(-)/Cipro(+)],  was added at 5 h of culturing there was 
a gradual decrease of survival ending with approximately 4 log CFU/mL of cell survival.  When 
G25 was added at the beginning of growth and Cipro was not added [G25(+)/Cipro(-)], the cell 
growth was delayed compared to being untreated and cell death occurred to an average around 5 
log CFU/mL.  The addition of G25 at the beginning of growth and the addition of Cipro at 5
 
h 
[G25(+)/Cipro(+)], decreases the viable cells to about 3 log CFU/mL.  The addition of G25 
immediately after inoculation decreases the viable cells in the culture, so when Cipro is added 
there is a lower amount of viable cells compared to cultures with Cipro treatment only. 
In Figure 2-7B, the G25 was added at the same time as Ciprofloxacin during 5 h of 
incubation.  When G25 was added at 5 h, there is a gradual decrease in cell survival to an 
average of 6 log CFU/mL at 9 h.  The cell survival with G25 and Cipro combined 




is about a log lower.  This shows that G25 in combination with Cipro has an adjuvant effect and 
causes faster killing compared to G25 alone or Cipro alone.  In Figure 2-6C, we show that the 
polymer alone (G0) does not have any antibiotic effect.  Although, there is less killing when G0 
and Cipro are added together, which may suggest there is some interference with the polymer 
causing deactivation or sequestering the antibiotic to inhibit it from going into the bacterial cell. 
 
Figure 2-7: (A) 20 mg/mL of G25 was added immediately after inoculation and then 1 µg/mL of 
Cipro was added after incubating culture for 5 h.  Samples were collected after 6, 7, and 9 h of 
incubating to determine cell survival after treatment. (B) 20 mg/mL of G25 and Cipro were 
added together or individually after incubating cultures for 5 h. (C) The polymer only (G0) was 
added immediately to the culture after inoculation and Cipro was added after 5 h of incubating. 
Adjuvant Effect of G25 and Gentamicin 
The above experiments were repeated using Gentamicin (Gent) instead of Ciprofloxacin 
to see if there were synergistic effects. Figure 2-8A shows that by adding G25 at the beginning of 




from 5 h of growth to 9 h of incubation; whereas, the killing of Gent only [G25(-)/Gent(+)] has 
only about a log of killing from 5 h to 9 h of treatment.  When G25 and Gent are added together 
[G25(+)/Gent(+)] there is a synergistic effect of about 3 logs of killing after 9 h of incubating .   
In Figure 2-8B, G25 is added at 5 h with Gent [G25(+)/Gent(+)] and there is more killing 
than compared to Gent alone.  The log CFU/mL count decreases at each hour and has about a 2 
to 3 log decrease in cell survival.  This shows there is a synergistic effect if not a greater effect 
on the susceptibility of P. aeruginosa to Gent when G25 is present to reduce the available iron. 
 
Figure 2-8: Survival of P. aeruginosa during log phase when treated with G25 and/or Gent. (A) 
20 mg/mL of G25 was added immediately after inoculation while 24 µg/mL of gentamycin was 
added after incubating the culture with or without G25 for 5 h.  Samples were collected after 6, 
7, and 9 h of incubation to determine cell count by CFU/mL.  There were about 2 logs of 




of Gent and polymer compared to Gent only. (B) Gentamicin (24 µg/mL) and G25 (20 mg/mL) 
was added after 5 hours and samples were collected after 6, 7, and 9 h to determine cell count.  
The final log CFU/mL was about 1.5 logs lower with Gent and G25 compared treatment of Gent 
or G25 only. 
Adjuvant Effect of G25 and Ciprofloxacin during Stationary Phase 
The effect of the bacteria’s susceptibility during the stationary growth phase was also 
tested in the presence of Cipro and when G25 was added immediately after inoculation or added 
after 12 h of incubation.  In Figure 2-9A, there is about a 4 to 5 log decrease from 12 h to 24 h in 
cell survival when cultures are treated with Cipro only [G25(-)/Cipro(+)].  In the G25 only 
treated cultures [G25(+)/Cipro(-)] the cell count varies but stays between 4 and 5 log CFU/mL  
This shows that there is a limited amount of viable cells that are able to persist in the presence of 
G25 for 24 hours  in the low iron conditions. When Cipro is added to the cultures treated with 
G25 from the beginning of growth [G25(+)/Cipro(+)] the log CFU/mL decreases from about 5 
log CFU/mL to 3 log CFU/mL showing that G25 decreases the number of surviving cells in 
combination with Cipro. 
When G25 was added after 12 h of growth in combination with Cipro, 
[G25(+)/Cipro(+)], there was about a log increase in killing compared to Cipro only, [G25(-
)/Cipro(+)], at 24
 
h seen in Figure 2-9B.  Interestingly, when G25 was added during stationary 
phase, it did not cause a decrease in cell count.  This could be explained by previous iron uptake.  
The iron that was necessary for cell growth could have already been taken in by the cell and 




brought into the cells, G25 would not be capable of removing iron from the media that would be 
needed for cell growth. 
 
Figure 2-9: Survival of P. aeruginosa during stationary phase when treated with G25 and/or 
Cipro. (A) The culture was inoculated and 20 mg/mL of G25 was added immediately.  The 
cultures were grown for 12 h to reach stationary phase and then treated with 1 µg/mL of Cipro.  
The effect of the polymer in combination with Cipro increased the amount of killing by 1.5-2 
logs killing compared to Cipro only or G25 only. (B) The addition of the polymer only, Cipro(-) 
and G25(+), after 12 h did not have a very significant decrease compared to Cipro(+) and G25(+) 
which saw about 2 logs more killing after 24 h than Cipro(+) and G25(-). 
Discussion 
 The iron sequestering polymer PAI-DHBA, which harbors moieties similar to the 
chelating ligands of siderophores released by bacteria have high iron affinity and specificity 




concentration to limit cell growth and also to cause cell death.  Concentrations below 20 mg/mL 
caused a slight delay in growth, but there was no killing effect (Figure 2-4).  This concentration 
must have irreversibly removed all iron from the media which prevented the bacteria from 
obtaining iron to use for the necessary functions of cell metabolism, such as the TCA cycle and 
DNA synthesis. This also suggests why G25 at 20 mg/mL had a better effect than when EDTA 
was tested.  EDTA is not capable of irreversibly chelating the iron, which allows the bacteria to 
compete for iron, leading to initial stagnation, followed by growth recovery (Figure 2-6).  The 
recovery is most likely because siderophores secreted by bacterial cells can compete for the iron 
bound to EDTA. In comparison, iron is irreversibly sequestered within the structure of the PAI-
DHBA polymer, where siderophores cannot access it, thus leading to iron starvation, which 
results in growth arrest and death.   
 It has been shown that iron chelators increase bacterial susceptibility to antibiotics,[5, 12] 
so we tested the efficacy of two types of antibiotics, the fluoroquinolone Ciprofloxacin and the 
aminoglycoside Gentamycin, in the presence of 20 mg/mL G25.  When both antibiotics and G25 
were added together, there was an increase of killing compared to the antibiotic alone or G25 
only, as seen in Figures 2-7 and 2-8.  When G25 was added at the time of inoculation, the cells 
were already at a disadvantage by not having access to iron for metabolic needs (Figure 2-7A 
and 2-8A).  This made the P. aeruginosa more susceptible to the antibiotics.  When G25 was 
added at the same time as Cipro (Figure 2-7B), the final log CFU/mL was similar to when G25 
was added at the beginning.  When G25 and Gent were added at the same time (Figure 2-8B), 




 During the stationary phase of growth, cell metabolism changes compared to the log 
phase of growth, so we tested cells in stationary phase for an adjuvant effect with the iron 
sequestering polymer and ciprofloxacin.  In Figure 2-9A, the presence of G25 only, delayed the 
growth after 12 h, but there was a similar log CFU/mL at 24
 
h of incubation.  The cell count was 
very low which shows the limited amount of bacteria that could survive in the depleted 
concentrations of iron.  When Cipro was added to the cultures that had been treated with G25 for 
12 h, there was approximately an additional 2 logs killing compared to Cipro or G25 only.  This 
shows the stability of G25 and its ability to chelate iron for long periods of time. Interestingly, 
when G25 was added after 12 h of growth, there was not a significant change in cell count after 
24 h; although there was an additional killing when Cipro was added in combination to G25 at 
12 h compared to Cipro alone treatment.  G25 effects the growth because it is removing an 
essential element from the bacteria, but by stationary phase the bacteria has been able to take the 
necessary amount of iron and store it in iron storage proteins.  When Cipro was added, it could 
add more stress to the cells which is then compacted with the addition of G25.  This could lead to 
the increase killing compared to Cipro only. 
 These results show the PAI-DHBA iron sequestering polymer, G25, provides an adjuvant 
effect with two types of antibiotics and is capable of irreversibly removing iron from the 
environment to inhibit cell growth and cause cell death.  This kind of treatment is promising to 
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Chapter 3 :  Iron Mobilization from BfrB is Essential for Iron 
Homeostasis in P. aeruginosa 
Introduction 
 Iron is an essential metal used as a cofactor or prosthetic group for enzymes that 
participate in many cellular functions and metabolic pathways, including electron transport, 
glycolysis, DNA synthesis, the citric acid  cycle (TCA), oxygen transport, nitrogen fixation, and 
defense against toxic reactive oxygen species [1-3].  Although iron is essential, it has poor 
bioavailability and the free metal ion can catalyze the formation of hydroxyl radicals [4]. At 
physiological pH the ferric ion (Fe
3+
) has a solubility of approximately 10
-18
 M [5]. Free ferrous 
(Fe
2+
) iron can readily oxidize to ferric iron in the presence of hydrogen peroxide to form 
hydroxyl radicals, in a reaction known as the Fenton reaction [6]. There is no innate defense for 
hydroxyl radicals, which are extremely reactive and detrimental to living cells because they 
damage proteins and DNA [6]. Consequently, the concentration of free intracellular iron in cells 
is strictly regulated [6].  
 Bacteria have iron storage proteins known as ferritin-like molecules, which play 
important roles in iron homeostasis by storing iron and ameliorating iron-induced toxicity, but 
also by providing a source of iron when bacteria encounter low iron conditions [3]. There are 
three known ferritin like molecules in bacteria, bacterial ferritin (Ftn), bacterioferrin (Bfr), and 
DNA protection during starvation (DPS) [7].  Ferritins are found in all domains of life including 




DPS are present in bacteria and archaea [7].  Bacterial ferritins and bacterioferritins are 24-mer 
proteins with similar spherical and hollow structures, assembled from a single type of subunit, 
which can hold approximately 4500 iron ions in their hollow interior cavity [8].  The structure of 
DPS differs from Ftn and Bfr in that DPS is assembled from only 12 subunits and can 
accumulate up to 500 iron ions [7]. In E. coli, DPS  binds to DNA and protects it from iron-
induced oxidative degradation [9].  Consequently, among ferritin-like molecules in bacteria, only 
Ftn and Bfr are thought to function primarily as iron storage proteins. 
In P. aeruginosa, like other bacteria, it is now known that both Ftn and Bfr are present 
[10].  When bacterioferritin was first isolated from P. aeruginosa, it was proposed that it 
consisted of two distinct types of subunits, α and β [11].  Further investigation established two 
genes coding for ferritin-like molecules in P. aeruginosa, which were termed bfrA and bfrB [12], 
and it was assumed that the products of these genes constitute each of the subunits that constitute 
P. aeruginosa Bfr. This was later questioned based on the different genetic regulation and 
structural differences of the two genes [13, 14]. By mining published data on the genetic and 
transcriptional response of P. aeruginosa cells at low and high iron conditions, it was revealed 
there were differences in bfrA and bfrB transcription.  In a study completed by Palma et al.,  only 
the bfrB gene was reported to respond to high iron concentrations during exponential phase, 
while there was no change in bfrA transcription [14].  It was shown during stationary phase that 
bfrA is slightly up-regulated in response to high iron concentrations [11].  It has also been 
suggested that bfrA may function in defense against oxidative stress, and it has been speculated 
that bfrA may provide iron for heme assembly and incorporation into catalase A [12].  More 




structurally and biochemically [15] and showed structural differences between the two proteins.  
Specifically, the product of the bfrB gene is a genuine bacterioferritin (BfrB), which binds 12 
heme molecules. In contrast, the product of the bfrA gene does not bind heme and lacks 
methionine 52 (or equivalent residue), which coordinates heme molecule in bacterioferritins. 
Hence the name BfrA is a misnomer, which has been changed to FtnA [13]. These findings 
demonstrated that in P. aeruginosa, like in most bacteria, there are two types of ferritin like 
molecules, which are now termed FtnA (formerly BfrA) and BfrB. It was also shown there are 
different requirements for the release of iron from BfrB and from FtnA in vitro.  For iron to be 
mobilized from the core of BfrB, Bfd (bacterioferritin associated ferredoxin) is required, whereas 
mobilization of iron from FtnA does not require a Bfd [1, 13, 16]. In multiple pathogens that 
contain a bacterioferritin including P. aeruginosa, the bfd gene is located adjacent to the bfrB 
gene [8].  For iron release from FtnA, only NADPH and a reductase (Fpr) are needed for rapid 
iron release in vitro [7]. It is curious why there would be this redundancy to contain two iron 
storage proteins, unless one of the proteins participated in other functions.   
 In our lab, we have extensively studied the bacterioferritin (BfrB) from P. aeruginosa 
and its associated ferredoxin, Bfd.  We have shown through in vitro studies that mobilization of 
iron from the BfrB core requires Bfd [8, 17]. We obtained the co-crystal structure of the 
BfrB:Bfd complex, which confirmed the interaction between the two proteins [8].  The structure 
also provided a look into the pathway for the electrons to move from the [2Fe-2S] cluster in Bfd 
to the heme in BfrB, and then into the core to reduce the iron (III) to iron (II), which can be 
released from the protein (Figure 3-1).  The primary residues in BfrB that interact with Bfd 




by mutating residues to alanine (Figure 3-2) [17].  The binding affinity of the BfrB: Bfd complex 
was determined to be around 3 µM. When the BfrB residues leucine 68 and glutamate 81 were 
mutated to alanine, the binding affinity became undetectable [17]. The double mutant was also 
incapable of releasing iron from mineralized BfrB in the in vitro iron release assays [17]. 
 
Figure 3-1: Electron path from the [2Fe-2S] cluster in Bfd to reduce Fe
3+
 in the core of BfrB. 
BfrB is shown in grey and Bfd is the faded cyan. Electrons travel from the [2Fe-2S] cluster of 
Bfd to the heme and then to the Fe
3+




is released outside 





Figure 3-2: BfrB:Bfd interaction site.  The BfrB surface is shown in green and grey, Bfd 
residues are in cyan. Key residues from BfrB that interact with Bfd include E85, E81, L68, and 
N70. The oxygen atoms in E85 and E81 interact with M1 from Bfd and there is a cleft between 
E81 and L68 that allows for Y2 from Bfd to anchor at the BfrB surface [17]. 
In this research, we analyze the disruption of iron homeostasis when we inhibit the BfrB-
Bfd interaction in Pseudomonas aeruginosa. To this end, gene knockout mutants Δbfd and 
ΔbfrB, and the chromosomal double point mutation on the bfrB gene, called bfrB*, were 
prepared. The double mutation was introduced into the bfrB gene of P. aeruginosa on the basis 
of our in vitro results, which showed that the BfrB L68A/E81A double mutant does not interact 
with Bfd, leading to inhibition of iron mobilization of iron stored in BfrB [17].  We show that 
iron is stored during late log phase in BfrB and is used in stationary phase when iron 
concentrations in the environment become depleted. In response to lacking Bfd and disrupting 
the protein-protein interaction between BfrB and Bfd, the mutants experience iron starvation at a 
faster rate than WT.   We show that by inhibiting the BfrB:Bfd interaction in P. aeruginosa cells 




these mutants.  Consequently, there is lower free intracellular iron concentrations in the Δbfd and 
bfrB* mutants relative to wt.   The ability to mobilize iron stored in BfrB gives wt P. aeruginosa 
cells an advantage when placed in low iron growth conditions compared to the Δbfd or bfrB* 
mutants.  Under these conditions, we show the function of Bfd binding to BfrB is an essential 
aspect to regulating free intracellular iron concentrations in P. aeruginosa.  
 
Experimental 
Bacterial strains, media and growth conditions 
All chemicals were obtained from Fisher Scientific unless otherwise stated. The bacterial 
strain Pseudomonas aeruginosa PA01 was purchased by the University of Washington, Manoil 
Lab. The mutant and complemented strains ΔbfrB, Δbfd, ΔbfrB* were prepared by Jacqueline 
Stevens in the Chandler Lab at the University of Kansas. Pseudomonas Isolation (PI) media (20 
g/L peptone, 1.4 g/L magnesium chloride
 
, 10 g/L potassium sulfate, 25 mg/L Irgasan (Sigma-
Aldrich), and 20 mL/L glycerol, pH 7.0) was used for normal growth conditions.  An acidic 
stock solution of 20 mM FeS04-7H2O was added to the PI media to give 8 or 10 µM Fe final 
concentrations.  All strains were kept on Pseudomonas Isolation Agar (PIA) (BD Biosciences).  
Cultures (250 mL PI media in 500 mL Erlenmeyer flasks) were inoculated from a 5 mL 
overnight culture grown in PI media to an optical density at 600 nm (OD600) of 0.001 and 
incubated with shaking at 230 rpm and 37 °C.  This growth condition was used for all 
experiments but for growth in low iron.  Glassware was rinsed with 1% Trace Select nitric acid 




To culture cells in low iron conditions we used Phosphate media. Phosphate media 
consists of 24 g/L HEPES, 0.93 g/L Ammonium sulfate, 3.245 g/L succinic acid, 615 mL of 2 
mM K2HPO4 (Sigma-Aldrich) and 385 mL of 2 mM KH2PO4 (Sigma-Aldrich) at pH 7.0. The 
following trace metals were added to 1 L of phosphate media: 2 mL of 1 M MgSO4, 100 μL of 4 
M CaCl2, 10 μL 15 mM Ammonium molybdate, 1 mL 17 mM EDTA, 300 μL 10 mM CuSO4, 
100 μL 20 mM Co(NO3)2, 100 μL 94 mM Na2B4O7, and 100 μL 76 mM ZnSO4. 
Growth Curves  
P. aeruginosa was cultured in 250 mL PI media with 7-8 µM as described in growth 
conditions.  Samples (100 μL) from 250 mL PI cultures were removed every 2 h, serially diluted 
in phosphate buffer saline (PBS), pH 7.4 and plated on PIA plates. Plates were incubated for 18 h 
at 37 °C.  Colony forming units per mL were determined by counting the number of cells, 
multiplying by the dilution factor and dividing by the total volume plated. 
Imaging Iron Storage in Bacterioferritin 
P. aeruginosa strains were cultured in 250 mL PI media with 7-8 µM as described in 
growth conditions.  Samples (15 mL) were collected 6, 8, 10, 12, 24, 36, and 48 h post 
inoculation and centrifuged in 50 mL conical tubes at 4,000 rpm and 4 °C for 15 min.  The 
supernatant was removed and the cell pellets resuspended in 1 mL of 50 mM Tris-base buffer 
(pH 8.0) containing 5 mM EDTA and 200 mM NaCl, transferred to a 1.7 mL microcentrifuge 
tube and centrifuged for 10 min at 13,300 rpm, 4 °C.  The supernatant was removed and the cell 
pellet was frozen at -80 °C overnight. Frozen cell pellets were thawed at room temperature and 




incubated at 37 °C for 45 minutes.  50 µL volume of 10 μg/mL DNase (Gold-Bio) in 50 mM 
Tris-base buffer (pH 8.0) containing 5 mM CaCl2, 10 mM MgSO4 was added. 5x native loading 
dye (5.9 mL water, 0.5 mL glycerol, 0.4 mL β-mercaptoethanol, 0.4 mL 1% bromophenol blue, 
and 0.5 mL 1 M Tris-HCl pH 6.8 ) was added in a 1:1 ratio to cell supernatant and 80 μL of the 
resultant solution was loaded onto an 8% native PAGE gel in a Protean II XI electrophoresis cell 
(Bio-rad). The gel ran for 2 h at constant 25 mA and then 6 h at constant 35 mA. The 
electrophoresis buffer was kept cold (close to 4 °C) during the separation experiment to prevent 
over-heating. The native gel was stained for 10 min in the dark by immersion in a solution 
containing Ferene-dye (0.044 g Ferene, 125 µL thioglycolic acid, 2.4 mL acetic acid and 117.4 
mL water). 
Growth Curves in Low Iron Media 
P. aeruginosa strains were cultured in 250 mL PI media with 7-8 µM as described in 
growth conditions for 10 hours or 24 hours. 1 mL samples from each time point were removed 
from 250 mL culture, pelleted and resuspended in Phosphate media. The OD was measured and 
cells were diluted to an OD600= 0.01 in a total culture volume of 200 µL in a 96 well plate with 
the lid.  The OD was measured for 24 hours in a Spectramax i3x plate reader set at 37 °C.  The 
plate reader was set to orbital shake on high every- other 15 minutes while recording the OD600 
every 30 minutes.   
Pyoverdine Release  
The release of pyoverdine was studied in plates and in liquid culture. In the case of plates, 




Luria-bertani media (25 g/L, pH 7.0). 100 μL of overnight culture was serially diluted in PBS to 
10
6 
times. Ten 10 μL drops of the 10
6 
dilution was plated on PIA plates, dried at room 
temperature until no drop was visible, and incubated in the dark at 37 °C for 24 h. 
Complemented strains were grown in 1 mM IPTG (Gold-bio) added 5 mL overnight cultures.  
250 µL of a 20 mM IPTG stock solution, dissolved in water, was added to a final volume of 5 
mL LB.  5 µL of 1 mM IPTG was spotted on PIA plate and air dried before plating strains. The 
complemented strains were diluted as done for wt and mutants and spotted on the same location 
on the PIA plates as the dried IPTG drops.  Fluorescence was imaged by UV light. 
 To measure the release of pyoverdin in 250 mL PI liquid culture, at 12, 24, 36, and 48 
hours, 1 mL of culture was removed and centrifuged for 3 minutes at 13,300 rpm, 4 °C. The 
supernatant was added to 1 mL of chloroform.  The water phase was separated and diluted 1000x 
in 200 mM Tris pH 7.4 with 5 mM EDTA.  It was immediately measured using fluorescence by 
exciting at 400 nm and scanning from 425-600 nm.  Emission intensity at 460 nm was compared 
to CFU/mL to normalize the values between strains.   
Total Iron Analysis   
At 12 and 24 hours, 15 mL of 250 mL PI culture were removed and centrifuged at 13,300 
rpm and 4 °C for 10 min. using a SS-34 Sorvall rotor. Cell pellets were resuspended in 1 mL of 
PI media containing 0.5 mM diethylenetriaminepentaacetic acid (DTPA) (Sigma-Aldrich). Cell 
pellets were washed twice with 1 mL PI media with 500 μM DTPA and centrifuged for 10 
minutes at 13,300 rpm, 4 °C.  The supernatant was removed by a pipette and cell pellets were 




concentrated HCl and 0.225 g of KMn04 in 10 mL of water).  Solution was thoroughly mixed by 
vortexing then placed in a hot water bath (70 °C) for 4-6 h, or until the solution became mostly 
colorless. Iron was analyzed by adding 300 μL of the iron detection reagent (6.5 mM ferrozine, 1 
M ascorbic acid, and 2.5 M ammonium acetate (Sigma-Aldrich)).  After 15 minutes the sample 
was centrifuged for 5 minutes at 13,300 rpm the absorbance at 564 nm was measured using a 
Varian-Cary UV-vis spectrophotometer. Iron concentration was determined using the epsilon 




.   
Iron Analysis in Spent Media 
Iron analysis in spent media was determined by sampling 2 mL into acid washed glass 
vials in triplicate from 15 mL of culture that had been centrifuged similar to total cell analysis at 
6, 12, 24, 36, and 48 h post inoculation.  The media was frozen and freeze dried with a Savant 
Speed Vac SC110 for approximately 4-5 h.  Organic matter from media was digested in 500 μL 
of digestion reagent for 2 hours with vortexing every 30 minutes in a 70 °C water bath.  Iron was 
analyzed by adding 300 μL of the iron detection reagent and vortexed to mix.  After 15 minutes 
the sample was centrifuged for 5 minutes at 13,300 rpm the absorbance at 564 nm was measured 
using a Varian-Cary UV-vis spectrophotometer. Iron concentration was determined using the 




.  To blank the spectrophotometer, an extra sample at 
each time point (6, 12, 24, 36, and 48 hours) was taken and digested as the other samples.  300 
μL of blank reagent (1 M ascorbic acid, and 2.5 M ammonium acetate) was added.  The sample 
was vortexed to mix, incubated for 15 minutes at room temperature, and centrifuged for 5 




spectrophotometer for the 6 hour samples, the 12 hour sample was used to blank the 12 hour 
samples, and so forth for each time point. 
EPR of Free Intracellular Iron  
  In the 250 mL PI media cultures, the entire culture was collected at 12 and 24 h of 
incubation.  100 μL of culture was collected from each strain in triplicates, serially diluted in 
PBS and plated on PIA to determine cell counts.  The cultures were centrifuged for 12 min at 
4500 rpm and 4 °C.  The cell pellets were resuspended in 6 mL of PI media with the addition of 
1 mL of 100 mM DTPA in PI media pH 7.4 and 1 mL of 200 mM deferoxamine (DFO) (Sigma) 
in PI media pH 7.0 and incubated for 10 min at 37°C, 230 rpm.  The cells were centrifuged at 
4000 rpm, 4 °C for 10 minutes and washed twice with ice cold PBS.  The cells were resuspended 
with 300 µL of PBS with 10% glycerol, packed into EPR tube, and frozen in dry ice and acetone.   
Results 
BfrB is the Primary Iron Storage Protein in P. aeruginosa PA01 
Given that there are two types of iron storage proteins in P. aeruginosa [13], FtnA and 
BfrB, it is important to determine whether iron is stored in both proteins, or if the cell deposits 
iron reserves primarily in one of them.  To determine this, cultures of wt and the ΔbfrB mutant 
were grown in PI media containing about 8 µM of iron. Samples were collected from the cultures 
at different times, the cells were lysed, the proteins separated on a native PAGE gel, and the gel 
was stained with the dye Ferene, which specifically stains iron stored in iron storage proteins 
[18].  The presence of a blue stain signifies stored iron (Figure 3-3A); the darker the blue color, 




as standards. Figure 3-3A shows that in the wt strain, iron begins to accumulate to detectable 
levels during the late log phase of growth (6-8 hours), according to the growth curve in Figure 3-
3B. It is noteworthy that iron only accumulates in BfrB.  In agreement, in the mutant where the 
bfrB gene has been deleted (ΔbfrB) iron is not accumulated at all.  In the absence of BfrB, if 
FtnA would function as an iron storage protein, there would be a stain present, but there is not.  
This suggests that under the experimental conditions, P. aeruginosa PA01 uses BfrB as the 
primary iron storage protein.  
Figure 3-3A also shows that in wt P. aeruginosa iron stored in BfrB is utilized during the 
stationary phase, when iron in the media reaches low concentrations (~ 2 µM Fe): Figure 3-3C, 
the media started with approximately 10 µM Fe and it shows that iron is taken by the cells 
relatively rapidly until the concentration of iron in the media reaches approximately 2 µM, at 
around 24 h; beyond this time, iron is taken significantly more slowly. Inspection of Figure 3-3A 







Figure 3-3: Iron storage in BfrB.  (A) The recombinant (Rec.) mineralized BfrB and FtnA 
proteins were used as standards in the native PAGE gels and stained with the iron specific, 
Ferene stain.  Note that the native gel can resolve FtnA and BfrB.  The bands obtained from 
separating lysates of wt P. aeruginosa cells indicate that iron is accumulated in BfrB during log 
phase and in early stationary phase. Cell growth is depicted by the growth curve shown in (B).  
Note that lysates of the ΔbfrB mutant show that there is no accumulation of iron, which indicates 
that BfrB is the primary iron storage protein in P. aeruginosa. The plot in (C) shows the rate at 




Δbfd and bfrB* Mutants have Iron “stuck” in BfrB 
 When grown in PI media containing ~ 7-8 µM Fe, all mutant strains grow similarly to wt, 
as seen in the growth curves shown in Figure 3-4A.  As mentioned previously, our in vitro 
studies showed that Bfd is necessary for mobilizing iron from BfrB [8]. Interestingly, we made 
similar observation in P. aeruginosa cells:  The native PAGE gels in Figure 3-4B show that in wt 
P. aeruginosa cells the iron stored in BfrB is mobilized, so that it becomes undetectable by the 
24
th
 h of culture. In contrast, in Δbfd and bfrB* mutants, the iron stored in BfrB stays in the 
protein even at 48 h of culture. These results clearly demonstrate that the insights gained from 
the in vitro studies are actually replicated in the cells. Bfd is necessary for iron release and when 
it is not present, as in the Δbfd mutant, or is unable to bind BfrB, as in bfrB* mutant, then iron is 
not mobilized from the core of BfrB.  It should be noted, the standard for bfrB* on the native gel 
is the recombinant BfrB with the single mutation E81A. The double point mutation E81A/L68A 
in bfrB*, and more specifically the replacement of a charged residue (E81) for a non-charged 
alanine, changes the size to charge ratio of BfrB, which results in different mobility of the mutant 





Figure 3-4:  Growth curve and iron storage of wt and mutants. (A) When the cells are grown in 
iron sufficient media (> 5 μM), the wt and mutant cells grow at the same rate and to similar cell 
density. (B) Native PAGE gels showing that iron is stored in BfrB in all strains. Although the 
iron concentration in the media at the start of the experiment is the same for all strains, the wt 
cells need to mobilize iron stored in BfrB after 24 h of culture, whereas iron stored in BfrB of the 
Δbfd and bfrB* mutants appears to be “stuck”.  These observations indicated that without Bfd, or 
the ability of Bfd to bind to BfrB (bfrB*), iron is irreversibly stuck in BfrB.  The recombinant 
protein BfrB E81A is used for the standard for the bfrB* native gel.  
Δbfd and bfrB* Mutants Release Greater Amounts of Pyoverdine 
 The consequences of irreversible accumulation of iron in BfrB in the Δbfd and bfrB* 
mutants causes a disruption in iron regulation.  One manifestation is the increased release of 
pyoverdine (Pvd) from the two mutants compared to the wt strain.  Pvd is a siderophore (high 
affinity Fe
3+




Although all the strains are cultured in media with the same concentration of iron, the Δbfd and 
bfrB* mutants, which are unable to utilize iron stored in BfrB, we suspect they feel the need to 
obtain more iron from the environment. Pvd is a fluorescent molecule so its fluorescence can be 
observed when illuminated by the light of a transilluminator. Figure 3-5A shows the results from 
overnight cultures of wt, Δbfd,  and bfrB* that were serially diluted, plated on PIA plates, and 
then incubated in the dark at 37 °C for 24 h.  These plates were illuminated with a UV-light and 
imaged.  The images show that the Δbfd and bfrB* mutants release much more Pvd than the wt 
strain.  To show that large secretion of Pvd by the mutants is due to the absence of the bfd gene 
or the double mutation made in the chromosome in bfrB*, the bfd and bfrB mutants were 
complemented by expression of the bfd or bfrB genes from a neutral site in the chromosome.  As 
can be seen in Figure 3-5B, the complementation causes a decrease in Pvd release in both 
mutants.  This shows that Pvd release in the mutants is related to iron getting stuck in BfrB and 
causes the bacteria to feel like it is in low iron conditions.  Once the iron is released from BfrB, 
as seen in the complemented strains, the bacteria no longer feels iron starved and does not need 
to release high concentrations of Pvd. 
 The release of Pvd in the liquid cultures was studied as a way to quantitate Pvd release 
and to correlate the observations of iron uptake, as judged by measuring iron in the media at 
different times of culture.  Figure 3-6A shows that the different strains take iron from the media 
at different rates.  The wt strain exhibits fast intake of iron during the log phase of growth, and 
once it reaches stationary phase (after 24 h) the rate of iron intake slows down and levels off 
around 2 µM.  Interestingly, ΔbfrB has a slower rate of iron uptake, but by 48 h has undetectable 




it does not have the primary iron storage protein, it may take in smaller amounts of iron initially.  
At 48 h, the cell count is slightly higher compared to wt as seen in Figure 3-4A, so more cells 
could be utilizing the iron in the spent media which would lead to undetectable levels (less than 1 
µM).   In the Δbfd and bfrB* mutants, the rate of iron uptake is faster than that observed with wt, 
and does not level off; rather, iron in the media becomes nearly completely depleted, as judged 
by the detection limits of the analytical tool used (~ 1 µM).  At 24 h, when iron levels reach 
below 2 µM in the spent media for Δbfd and bfrB*, Pvd is released very aggressively, which 
indicates that the Δbfd and bfrB* mutants strongly sense iron starvation. In comparison, the wt 
cells release much less Pvd between 24-36 h, and the iron concentration in spent media remains 
between 2-3 µM. As the Δbfd and bfrB* cultures are incubated to 48 h, the fluorescence of Pvd 
normalized to cell density is more than 4.5 times greater than wt. The synthesis and release of 
Pvd, as well as the import of iron-chelated Pvd into the cells is energetically costly.  This would 
suggest the mutants sense very low levels of iron compared to wt, which is a strong indication 
that iron homeostasis is disrupted when the BfrB:Bfd interaction is blocked, either by the 
absence of Bfd (Δbfd), or by inhibiting the protein/protein interaction in bfrB*.  In the case of the 
ΔbfrB mutant, the free intracellular iron levels appear to be at a concentration that prevents the 






Figure 3-5:  The release of Pvd can be seen by shining UV-light on colonies plated on PIA.  (A) 
The wt strain releases some Pvd, but the Δbfd and bfrB* mutants release a much greater amount 
of Pvd, as seen by the fluorescent intensity surrounding the bacterial colonies.  (B)  The Δbfd and 
bfrB* mutants were complemented with the bfd and bfrB genes, respectively 
(ΔbfdminiTn7lacZbfd and bfrB*miniTn7lacZbfrB), which causes secretion of Pvd at levels lower 






Figure 3-6:  Iron left in spent media and the release of Pvd in cultures of wt and mutant P. 
aeruginosa strains.  (A)  The iron left in the spent media was measured overtime for all strains.  
ΔbfrB initially utilizes iron at a slower rate than the other strains, but has undetectable levels of 
iron at 48 h. The wt strain takes iron at a relatively fast rate through the log phase of growth and 
at a much slower rate during stationary phase, leaving behind around 2 µM in the media.  The 
Δbfd and bfrB* strains take iron at a fast rate through log and stationary phases until the levels of 
iron become undetectable at 24 h. (B) The release of Pvd can be measured by its fluorescent 
intensity.  The levels of Pvd were normalized for each strain by the cell count in log CFU/mL.  
Δbfd and bfrB* begin to release Pvd earlier and at a fast rate after 24 h, compared to the slow and 
small amount of Pvd release by wt and ΔbfrB.  The release of Pvd correlates to the same time 




Mutants have Lower Levels of Free Intracellular Iron  
Levels of total intracellular iron were measured after culturing the wt or mutant strains 
for 12 and 24 h in PI media containing 7-8 µM Fe (Figure 3-7A).  These time points were chosen 
because the results summarized in the native PAGE gels of Figure 3-4 indicate that iron storage 
in BfrB is similar for all strains at 12 h (except ΔbfrB), whereas at 24 h iron in BfrB has been 
mobilized in the wt strain, but it remains “stuck” in BfrB in the Δbfd and bfrB* strains.  There 
are no significant differences in the total iron levels of wt, Δbfd and bfrB* since the standard 
deviations overlap the averages of each strain at 12 h and 24 h. In contrast, the total iron levels in 
the ΔbfrB mutant are approximately 50% of those observed in the wt, Δbfd and bfrB* strains. 
Although this information may be interpreted to suggest that the higher levels of intracellular 
iron in the wt, Δbfd and bfrB* strains is due to iron stored in BfrB, it is also important to note 
that the ΔbfrB mutant takes in less iron from the media, as shown in Figure 3-6A.. Hence, it 
appears the ΔbfrB mutant takes less iron than wt P. aeruginosa, which leads to significantly 
lower intracellular iron in ΔbfrB. Although the analysis of total intracellular iron content is 
informative, it does not reveal important details about what is occurring in the bacterial cell with 
respect to iron homeostasis. To gain additional insights into iron regulation and iron homeostasis, 
we performed EPR experiments to measure the free intracellular iron content.  The free 
intracellular iron content is iron that is unincorporated and may be in transit or bound to the 
surface of biomolecules [20, 21]. 
To measure free intracellular iron, cells were sampled at 12 and 24 h, and the samples 
were prepared for EPR analysis as described in the Experimental Section.  The results are 




in the wt and ΔbfrB mutant are similar, while the free iron levels in the Δbfd and bfrB* mutants 
are approximately ½ that of wt P. aeruginosa.  At 24 h the levels of free intracellular iron in all 
mutant strains are lower than in the wt cells.  These results clearly show that in absence of BfrB, 
or when the BfrB:Bfd interaction is inhibited, there is a disruption in iron regulation. 
It is interesting to think in terms of the levels of total and free intracellular iron: In the 
case of the ΔbfrB mutant, the total iron levels at 12 h are approximately ½ those in the wt strain, 
yet the free iron levels are nearly identical. At 24 h, the total iron levels remain low, and there is 
a decrease in the levels of free iron, although these values remain higher than in the Δbfd and 
bfrB* mutants. The relatively “normal” levels of free iron may explain the “reluctance” of ΔbfrB 
cells to secrete Pvd, despite the fact that the cell becomes iron deficient, as indicated by the total 
iron levels.  In the case of the Δbfd and bfrB* mutants, the free iron levels are consistently lower 
that in the wt strain, however, the levels of total iron are very similar to wt at 12 h, and only 
modestly decreased at 24 h. Considering that iron “stuck” in BfrB contributes to the total iron 






Figure 3-7 Levels of total intracellular iron measurements and free intracellular iron at 12 and 
24 h. (A) The total iron in the cells at 12 and 24 h is similar for wt, Δbfd and bfrB*.  ΔbfrB is 
lower at both time points. (B) Levels of free intracellular iron at 12 and 24 h. The free 
intracellular iron levels at 12 h are similar in wt and ΔbfrB but lower in Δbfd and bfrB*.  At 24 h 
the levels of free intracellular iron relative to wt are lower in the ΔbfrB mutant and even lower in 
the Δbfd and bfrB* cells. 
Iron Storage and Mobilization from BfrB Gives wt P. aeruginosa an Advantage to 
Overcome Low Iron Conditions 
The mobilization of iron stored in BfrB allows P. aeruginosa cells to utilize iron reserves 
when the iron concentration in the environment becomes depleted.  In the following experiments 
we show how wt cells have a growth advantage when iron can be utilized from BfrB:  The 
strains were grown in PI media containing 8 µM Fe for either 10 or 24 h and then transferred to 




Figure 3-4) showed iron stored in BfrB at 12 h, but at 24 h most (if not all) the iron stored in 
BfrB has been mobilized.. Figure 3-8A shows growth curves in iron-depleted media inoculated 
with cells containing iron in BfrB (10 h inoculum). The curves show that wt cells have a growth 
advantage over the mutants. In comparison, when iron-depleted media is inoculated with cells 
that do not have significant iron stored in BfrB (24 h inoculum) the wt cells grow at the same 
rate as the mutants seen in Figure 3-8B. 
 
Figure 3-8:  The wt strain has a growth advantage when iron stored in BfrB can be utilized.  (A) 
Strains were grown in 8 µM Fe media for 10 h and then transferred to iron-deplete media. The wt 
cells, which can utilize iron stored in BfrB, grow faster and reach a higher cell density compared 
to the Δbfd and bfrB* mutants, which are unable to utilize iron stored in BfrB. (B) Strains were 
grown in 8 µM Fe media for 24 h, so the wt cells had already mobilized the iron stored in BfrB. 
Unable to have access to iron reserves, the wt cells grow at a similar rate as the mutants in iron 





It has been unclear the exact role of the iron storage proteins, FtnA and BfrB in P. 
aeruginosa PA01.  The role of FtnA is still being investigated, but through our results we can 
suggest that the primary role of iron storage belongs to BfrB.  As seen in the iron-stained native 
PAGE gels in Figure 3-4, iron is consistently observed in the bands that align with the bands 
corresponding to the recombinant BfrB protein.  In contrast, native PAGE gels obtained with cell 
lysates of the ΔbfrB mutant there are no iron-stained bands, indicating that iron is not 
accumulated in iron storage proteins in the mutant cells.  These observations lead to the 
important conclusion that in P. aeruginosa cells, FtnA does not accumulate iron, even when 
BfrB is missing. Consequently, BfrB functions as the iron storage protein in P. aeruginosa, 
whereas the function of FtnA, although yet not understood, is not iron storage. 
The function of iron storage proteins has been described as storing iron to prevent 
oxidative stress from free iron and to also provide a supply of iron when the cell encounters low 
iron conditions.  This latter function of iron storage and subsequent mobilization under iron 
limiting conditions has been demonstrated in this work for BfrB, as can be seen in the NATIVE 
PAGE gels in Figure 3-4. When the iron concentration in the media decreased below 3 µM 
(Figure 3-3A and 3-3C) the wt cells mobilize iron stored in BfrB.  Utilization of iron stored in 
BfrB decreases the need to release high levels of Pvd (Figure 3-6B). In contrast, when we 
prevent the bacteria’s ability to obtain iron stored in BfrB, such as in the Δbfd and bfrB* mutants, 
we also disrupt iron regulation.  Iron that gets stuck in BfrB is no longer accessible to the 
mutants; therefore, they begin to feel iron starved, despite the fact that the cells continue to 




attempt to sequester extracellular iron.  Interestingly, we see through EPR results that the free 
intracellular iron concentration in these mutants is lower than wt.  One would think that if high 
concentrations of Pvd are being released because the cells sense low iron conditions, then iron 
would go straight to the free intracellular iron pool when iron was brought into the cell.  This 
process does not appear to be happening, but instead, it is probable that iron incorporated from 
the media is routed by the cell directly into BfrB.  From these results, we hypothesize the role of 
BfrB could also be that of “iron depot and distribution center”.  Consequently, iron brought into 
the cell is routed into BfrB. In this context, the BfrB:Bfd interaction, which enable iron 
mobilization from BfrB also functions to regulate the levels of free iron in the cells, which in 
turn enable Fur, the master iron regulator to activate or suppress the transcription of genes 
involved in iron uptake, such as Pvd synthesis. In addition, it is possible that the BfrB:Bfd 
interaction is also important to mobilize iron for incorporation into iron utilizing proteins, such 
as heme- and iron sulfur cluster- containing proteins and enzymes.      
Recovering stored iron from BfrB gives wt an advantage when growing in low iron 
media (Figure 3-9A).  These types of conditions resemble the low iron environment when 
pathogens invade a host. The host innate immune system resorts to nutritional immunity which 
prevents the bacteria from accessing essential nutrients such as iron [22].  Under such conditions, 
wt cells would be expected to use the iron stored in BfrB whereas the mutants would not be able 
to survive as well.  The mutants also produce large amounts of Pvd which makes the bacteria use 
a lot of energy to make and bring iron-bound Pvd back into the cell [23].  Also, the low free 
intracellular iron concentrations in the mutants would suggest that iron-utilizing proteins 




not attain their iron cofactors.  Ultimately, this would make the bacteria weaker and more 
susceptible the host immune system.  Testing the mutants’ virulence in animal models is 
currently in progress. 
The ΔbfrB mutant has brought up more questions than answers involving how the 
bacteria deals with not having a primary iron storage protein.  The cell is able to defend itself 
from bringing in too much iron, but it is still capable of growing and surviving in similar growth 
conditions as wt. Nevertheless, total iron analysis indicates that the ΔbfrB are iron deficient, and 
consequently may also be less fit to fend against adverse conditions, such as those furnished by 
the host immune system. Future studies will be completed to understand how iron is processed in 
this mutant.  Studies with the Δbfd and bfrB* mutants have demonstrated the essential function 
of iron mobilization from BfrB in iron homeostasis.  From these results, we can postulate that 
BfrB could be an iron distributor in the cell. In conclusion, disrupting iron release from BfrB 
does disrupt iron homeostasis in P.aeruginosa. These findings have provided new and previously 
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Chapter 4 : Dynamic motions in bacterioferritin are necessary for 
ferroxidase activity 
Introduction 
Iron is an essential element for multiple functions in bacteria, but needs to be tightly 
managed in the cell.  Due to the ability of free Fe
2+ 
to cause oxidative stress in the cell and Fe
3+ 
to rust out in aerobic conditions, the cell has developed iron storage proteins to store iron.  
Bacterioferritins (Bfr) are 24-mer, heme containing iron storage proteins that belong to the 
ferritin superfamily, but are specific to only bacteria (Figure 4-1A and 4-1B) [1].  The structure 
and function of the bacterioferritin (BfrB) in P. aeruginosa has been extensively studied in our 
laboratory.  It has been shown that the iron ions are stored in the cavity of Bfr as a ferric 
hydroxyphosphate molecule [2].  For iron to be stored in the cavity of BfrB, free ferrous iron 
first needs to be oxidized at the ferroxidase centers.  Ferroxidase centers in bacterioferritins are 
located in the middle of each subunit. In BfrB the histidine 130 at the ferroxidase center provides 
a gating motion to channel the oxidized iron into the core of the protein (Figure 4-1C) [3]. In an 
iron free ferroxidase center, the crystal shows the histidine 130 is rotated away.  When iron is 
present, the H130 has two conformations.  It is either coordinated with iron or it is rotated in the 
away position [3].  This suggests ferrous iron from the exterior of the protein is capable of 
moving through the ferroxidase channel where a di-Fe
2+
 moiety are coordinated by the 
ferroxidase ligands including H130.  As the di-Fe
2+
 moiety is oxidized to di-Fe
3+
 the H130 
moves to its gate open state, allowing for Fe
3+





Figure 4-1:  Structure of BfrB: (A) Subunit dimer and associated heme.  Each subunit is made 
up of a 4-helix bundle (helices A-D), a perpendicular short helix (E), and a loop connecting the 
B and C helices (green).  (B) Cross sectional view of the full 24-mer structure of BfrB that shows 
the inside cavity where mineral Fe
3+
 is stored; the heme is highlighted in green.  (C)  The 
residues that make up the ferroxidase center are shown in grey when no iron is present and in 
green when iron is located in the center.  H130 is adopts two conformations, iron bound and iron 
free, when iron is present. 
The structure of BfrB suggests there may be communication between the interior of the 
protein and the outside pores.  The structures of bacterioferritins have eight 3-fold pores, six 4-
fold pores, and twenty-four B-pores.  The intersection of three subunits forms the 3- fold pores.  
The 3-fold pores consist of layers that alternate negative and positive charge (Figure 4-2A).  The 
intersection of four subunits makes up the 4-fold pores (Figure 4-2B).  The pore is lined by the 
corresponding E-helices. The narrowest portion is composed of two layers made by the side 
chains of four N148 and four Q151 (Figure 4-3A). The B pores are formed at the intersection of 




fold pore, so there is a total of twenty-four B-pores in the structure of a 24-mer bacterioferritin 
(Figure 4-2B). The narrowest section of the B-pores consists of residues D132 and T136 from 
one subunit and D34 from a different subunit (Figure 4-3B).  They are lined with hydrophilic and 
negatively charged residues. It has been suggested the B-pores could allow for Fe
2+
 to traffic 
across the Bfr shell [4].  Molecular dynamic simulations have shown that K
+ 
ions move in and 
out of the BfrB shell via B- and ferroxidase pores in wt BfrB, but traffic of ions was not observed 
to occur along the 3-fold or 4-fold pores [5].  The MD simulations also suggested that the traffic 
of K
+
 ions through the B-pores is possible due to the conformational movements in helix D.  In 
the MD simulations the C-terminal half of helices D exhibited recurring kinking/straightening 
and folding/unfolding transitions that are coupled to the lateral oscillations of the short E-helices 
that make up the 4-fold pores.  This results in a continual expanding and contracting of the B-
pores [5]. These results suggested there are cooperative dynamics in the 24-mer structure, which 






Figure 4-2:  (A) The 3 colored helices are highlighted to show one of the eight 3-fold pores.  (B)  
The colored helices make up one of the 4-fold pores.  Four B-pores (circled) surround each of the 
4-fold pores [6]. 
 
Figure 4-3: (A) Zoomed-in view of a 4-fold pore and a potassium ion (purple sphere) 
coordinated by the residues N148 and Q151.  (B) Zoomed view of a B-pore with a sodium ion 
(yellow sphere) coordinated by the residues D34, D132, and T136 [6]. 
The function of Bfr has been intensely studied, but it is still unknown how ions traffic in 
and out of the protein shell and how the movement of individual subunits in the 24-mer structure 
affects its function.  To further investigate the notion that Fe
2+ 
could traffic through the B-pores, 
a single mutation was introduced in BfrB to replace residue D34 with the hydrophobic 
phenylalanine at the B-pore (D34F BfrB).  This mutation was analyzed and compared to wt BfrB 
through molecular dynamic simulations, x-ray crystallography, and in vitro iron uptake assays. 
In the B-pore, D34 is a negatively charged residue, which is located at the narrowest section and 
coordinates a Na
+




residues, but it changed the flexibility and reactivity of the ferroxidase centers, which are located 
at considerable distance from the mutation site.  The MD simulations and the crystal structures 
helped explain the experimental observations by showing cooperative motions of the subunits, 
extending from 4-fold pores, via the B-pores, into the ferroxidase centers.  The ferroxidase 
centers are essential for efficient oxidation and mineralization of iron by the 24-mer 
bacterioferritin assembly.  The structural studies of BfrB mutants soaked in iron provided 
experimental support for iron traffic through B-pores, and an accumulation of iron binding sites 
in the interior surface of the mutant gives insight into the paths followed by iron and phosphate, 
from entry ports in the Bfr shell toward possible mineralization sites in the interior cavity. 
Experimental Procedures 
Site-directed Mutagenesis and Protein Expression 
The pET11a vector containing the bfrB gene [7] was mutated to D34F using the 
QuikChange II Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) using the manufacturer 
instructions. The following primer pair sequences were used:  
Forward: 5’GCATAGCCGCATGTGGAATTTTTGGGGCCTGAAACGTCTGG3’ 
Reverse: 5’CCAGACGTTTCAGGCCCCAAAAATTCCACATGCGGCTATGC3’ 
 PCR products were digested using Dpn I and transformed into XL1-Blue competent cells 
(Agilent Technologies) for DNA amplification. Plasmid DNA was isolated using the QIAprep 
Spin Miniprep Kit (QIAGEN), and the sequences verified by ACGT Inc. (Wheeling, IL). 
Recombinant DNA plasmids with the correct sequence were transformed into Escherichia coli 




expression. The protocols for protein expression, purification, and reconstitution with heme were 
carried out as previously described [3, 7]. 
Iron Mineralization Assay 
As-isolated BfrB (wt and mutants) contain only a very small amount of iron in their 
core.[7] Reconstitution with an iron core was carried out as previously reported:[7] A 10 mM 
solution of ferrous ammonium sulfate was prepared inside an anaerobic chamber (Coy 
Laboratories, Grass Lake, MI), placed in a container with a rubber septum, and removed from 
the chamber. Concentrated HCl was added to the ferrous ammonium sulfate solution (50 µL/100 
mL) through the septum with the aid of a Hamilton micro- syringe (final pH ≈ 2.0), and the 
resultant solution was titrated into a stirred solution of 2 μM BfrB and 1.0 mM TCEP in 100 mM 
phosphate buffer, pH 7.6, in aliquots delivering 50 Fe
2+
 ions/BfrB. Fifteen minutes were allowed 
after the addition of each aliquot; upon the addition of the total iron load (500 Fe atoms/BfrB), 
the solutions were stirred overnight at 4 °C and then passed through a Sephadex G25M size 
exclusion column (GE Healthcare). The iron content of the samples, prior and after 
reconstitution with iron, was analyzed using a colorimetric ferrozine-based assay[8] as reported 
previously:[7] 50 μL concentrated HCl was added to 50 μL of mineralized BfrB and the mixture 
was incubated for 15 min at room temperature prior to the addition of 50 μL of ascorbic acid (25 
mg/mL) and 250 μL of saturated sodium acetate. The concentration of iron was determined using 









Crystallization and Data Collection  
All crystallization experiments were conducted in Compact 300 or CombiClover 500 
(Rigaku Reagents) sitting drop vapor diffusion plates at 20 °C. Equal volumes of BfrB (10 
mg/mL in 100 mM potassium phosphate buffer, pH 7.6 and 1 mM TCEP) and crystallization 
solutions were equilibrated against 75 μL reservoir volume. Within 1 day, red prismatic crystals 
were obtained from Wizard 2 (Rigaku Reagents) condition E2 (35% (v/v) 2-methyl-2,4-
pentanediol, and 100 mM MES pH 6.5, 200 mM Li2SO4). Crystals were transferred to a fresh 
drop of crystallization solution, which served as the cryoprotectant, and stored in liquid nitrogen 
for data collection. Fe-soaked crystals were prepared by soaking native crystals for 10 min in 50 
mM FeCl2 freshly dissolved in crystallization solution and then frozen in liquid nitrogen. X-ray 
diffraction data were collected at the Advanced Photon Source beamline 17-ID (IMCA-CAT) 
using a Dectris Pilatus 6 M pixel array detector. 
Structure Solution and Refinement  
Intensities were integrated using XDS [9] via the XDSAPP [10] interface or the Autoproc 
[11] software package and the Laue class analysis, and data scaling were performed with 
Aimless [12]. All crystals were isomorphous (P212121, 24 molecules/asu) with the previously 
determined BfrB structure (PDB: 3IS7) [3]. Structure solution was conducted by molecular 
replacement using a single subunit from PDB: 3IS7 as the search model with Phaser [13]. All 
space groups with 622 point symmetry were tested in the molecular replacement searches. The 
top solution was found in the space group P6322 with four molecules in the asymmetric unit. 
Structure refinement and manual model building were conducted with Phenix [14] and Coot [15] 




observed. Structure validation was conducted with Molprobity [16]. Coordinates and structure 
factors were deposited to the Worldwide Protein Data Bank, and the accession codes are 
provided in Table 1. 






Values in parenthesis are for the highest resolution shell. 
b
Rmerge = ΣhklΣi |Ii(hkl) – <I(hkl)>|/ΣhklΣi Ii(hkl), where Ii(hkl) is the intensity measured for 
the ith reflection and <I(hkl)> is the average intensity of all reflections with indices hkl. 
c
Rfactor = Σhkl ||Fobs (hkl) | – |Fcalc (hkl) ||/Σhkl |Fobs(hkl)|; Rfree is calculated in an identical 
manner using 5% of randomly selected reflections that were not included in the refinement. 
d
Rmeas = redundancy-independent (multiplicity-weighted) Rmerge [12, 17]. Rpim = precision-
indicating (multiplicity-weighted) Rmerge [18-20]. 
e
CC1/2 is the correlation coefficient of the mean intensities between two random half-sets of data 
[20, 21]. 
f
 For the data sets obtained from iron soaked crystals or native data sets collected at the iron peak 
wavelength, the number of reflections used during refinement is greater than the number unique 
reflections reported for data scaling. This is because Friedel pairs were kept separate during 
refinement and the anomalous scattering factors for the Fe
2+
 atoms were refined. 
Molecular Dynamic Simulations  
(MD simulations were carried out by Dr. Huan Rui and Prof. Wonpil Im from the Molecular 
Biosciences Department and Center for Bioinformatics, University of Kansas) 
BfrB D34F was first immersed in a pre-equilibrated cubic water box of 160 Å in all three 
dimensions. This box is the same size as that used in the Grand Canonical Monte 




and the BfrB molecule were centered at the origin. The initial ion configurations were the same 
as those in the E2, E10, and E40 systems described previously; 29 the free K+ ion numbers are 
2840 (E2), 1042 (E10), and 714 (E40) and the numbers of HPO42‑  ions are 1231 (E2), 332 
(E10), and 168 (E40). In each of the D34F mutant systems, 24 K+ ions were added in the bulk 
solution to make the total charge of the systems neutral, and they were distributed with 2000 
Monte Carlo moves, which were either accepted or rejected based on Metropolis criteria. Water 
molecules within 2.4 Å from the ions and the BfrB heavy atoms were removed. The systems 
were then subjected to a 900-ps equilibration cycle with decreasing positional harmonic 
restraints on heavy atoms not including water oxygen. In the BfrB interior, the removed water 
molecules that were close to BfrB before the equilibration cycle were quickly replaced by water 
from the interior cavity of BfrB, creating small vacuum pockets. To overcome this problem, an 
additional sphere of pre-equilibrated water with 40 Å radius was added to the system on top of 
the other water molecules (also see ref [5]). Any of these newly added water molecules that were 
within 2.4 Å of either the BfrB heavy atoms or the other water molecules in the system was 
deleted. Each of the resultant systems was again equilibrated with diminishing positional 
harmonic-restraint potentials on the heavy atoms for another 900 ps and then subjected to a 40-ns 
production. All the simulations were carried out in NPT (constant particle number, pressure, and 
temperature) ensembles using the NAMD2.941 simulation package. The simulation inputs were 
obtained from the Quick MD Simulator module in CHARMM-GUI.42 The simulations were 
performed with CHARMM all-atom parameter set PARAM2243 including the dihedral cross-
term corrections (CMAP)44 and a modified TIP3P water model [23]. The van der Waals 




electrostatic interactions were calculated using the particle-mesh Ewald method [25] with a mesh 
size of ∼1 Å for fast Fourier transformation, κ = 0.34 Å−1, and a sixth-order B-spline 
interpolation. The temperature (300 K) and pressure (1 atm) were kept constant during all the 
simulations by Langevin dynamics and the hybrid Nosé-Hoover Langevin piston method, 
respectively. The Langevin damping coefficient was set to 1 ps−1; the decay period and damping 
time scale were 50 fs, respectively. 
Results 
D34F X-ray Crystal Structure 
The structure of the mutant D34F was determined by growing crystals of the purified 
recombinant protein (as-isolated) or by soaking the protein in Fe
2+
 solution (Fe-soaked).  The 
mutant was prepared to replace the negatively charged aspartate (which was observed to bind a 
Na
+
 ion in B-pores of BfrB) with the hydrophobic phenylalanine.  The major changes seen in the 
structure of the D34F mutant are in the B-pores and in the ferroxidase center.  The D34F mutant 
did not cause any change to the 4-fold pore compared to wt (Figure 4-4). In the 3-fold pore, the 
structure is almost identical, despite the presence of sulfate and iron ions (Figure 4-5).  The 
differences seen in the crystal structure of D34F compared to wt BfrB strongly suggested a 
decrease in the flexibility of the ferroxidase center ligands and changes in residue movement 
when crystals are soaked iron solution.  Prior to soaking crystals in iron solution, the D34F 
mutant did not have iron coordinated at the ferroxidase center, similar to wt. Soaking in iron 




of iron binding are different between wt and D34F BfrB. In addition, there was iron bound to 
locations at the different pores not seen in wt, and iron atoms were seen in the B-pores.   
 
Figure 4-4:  Zoomed-in view of 4-fold pore in (A) wt and (B) D34F BfrB. Top: view of a 4-fold 
pore from the interior cavity. Bottom: cross-sectional view.  Iron atoms are orange spheres, water 
molecules are yellow spheres, sodium ion is a purple sphere, nitrogen atoms are shown in blue, 





Figure 4-5: View of the 3-fold pore in wt and D34F BfrB.  The top row is a cross-sectional view 
of a 3-fold pore in the as-isolated structures.  The middle row is the same view as the top view 




in Fe-soaked crystals.  Fe atoms are the orange spheres, water molecules are yellow spheres, 
sulfur atom are green, oxygen atoms are red and nitrogen atoms are blue [6].  
Changes to B-Pores 
Side chains lining the B-pores are E66, D34, T136, and D132 in wt BfrB.  They form a 
corkscrew from the outer E66 to the inner D132 (Figure 4-6A). The bulky hydrophobic mutation 
(D34F) caused the E66 residue to rotate away from the pore as seen in the top image of Figure 4-
6B.  The relatively bulky phenylalanine (Phe) side chain not only blocks the pore but also 
disrupts the hydrophilicity of the corkscrew.  Not only is there an increase in water molecules 
seen at the pore, there is also the presence of an iron atom coordinated by D132 in the Fe-soaked 
structure.  In the crystal structure of another mutant prepared by our lab, with mutations made at 
the surface of the protein, C89S/K96C, we observed the presence of two Fe atoms.  One Fe atom 
was coordinated by D132 and the surface of the protein.  This location is where the Phe residue 
in the D34F mutant is also located.  The second Fe atom was coordinated by the residues D34 
and E66 which is similar to the iron atom found in the D34F mutant as is seen in the bottom 
picture of Figure 4-6B.  The crystallographic data shows that iron molecules are seen in the B-
pores.  In the case of D34F, the hydrophobic ring could possibly block iron from going through 
the pore which is why we see an iron atom on the inside of the pore.  The crystal structure data 
supports the previous published MD simulations that suggested the B-pore could be used to 






Figure 4-6:  Zoomed-in view of the B-fold pore in wt and D34F BfrB.  The top row shows a 
view from the exterior of the protein.  The bottom row is a cross sectional view with the grey 
subunit seen in the top row removed.  The water molecules are yellow spheres, the iron ion is 
shown as a magenta sphere, oxygen atoms are red, and nitrogen atoms are blue [6]. 
Ferroxidase Activity 
In the as-isolated proteins, both, wt and the D34F mutant do not have iron present in the 
ferroxidase center. Crystals of as-isolated protein soaked in an iron solution causes iron to be 
incorporated at the ferroxidase centers.  In the structures of Fe-soaked wt BfrB, two iron atoms 




approximately 4.1 Å, suggesting it is a di-Fe
2+
 site.  In the wt protein, the H130 side chain 
undergoes a conformational change from “gate open” to “gate closed” to allow entry of the 
oxidized iron into the core of the protein (Figure 4-7A).  The D34F mutant has iron bound at the 
ferroxidase center, but the H130 does not go through the similar conformational changes as wt.  
The H130 side chain stays in the “gate open” position and does not coordinate iron, and the E81 
side chain does not rotate, so the iron atoms are not bridged and coordinated by these residues 
(Figure 4-7B).  These observations made in crystallo suggest that the mutation made at the B-
pore disrupts the flexibility and dynamics of the iron ligands in the ferroxidase center.    
 
Figure 4-7:  View of the ferroxidase center, as-isolated (grey) and Fe-soaked (green). (A) In the 
WT structure of as-isolated protein the side chain of H130 is rotated away, but when the crystals 
are soaked in iron (Fe-soaked) the H130 side chain is observed in the gate open and gate closed 
conformations, which allow for the oxidized iron to be taken into the interior of the BfrB cavity.  
(B) The structure of the D34F mutant shows that even after soaking in iron the H130 side chain 




Iron Oxidation and Uptake  
Mineralization experiments were carried out with the purified proteins to investigate 
whether iron could be loaded into the core.  As stated in the experimental section, 500 Fe atoms 
were attempted to be loaded into the core of the proteins by adding 50 Fe atoms/ BfrB at the 
time. In this experiment, there are two competing reactions, (i) the oxidation of Fe
2+
 at the 





, which forms an insoluble ferric colloid.  The wt BfrB was capable of 
mineralizing (storing) 430 ± 22 Fe atoms; while in contrast, the D34F mutant was only able to 
store 110 ± 30 Fe atoms.  The oxidation rates were unable to be measured because the formation 
of the Fe
3+
-O spectroscopic signal is around 300 nm which can be found both outside and inside 
BfrB.  The inability of iron to be mineralized in the D34F mutant is likely a consequence of the 
effects caused by the mutation on the ferroxidase center flexibility, as suggested by the above-
described analysis of the X-ray crystal structures:  If the conformational flexibility of the 
ferroxidase center ligands is impaired, then the ferroxidase center is unable to coordinate the di-
Fe
2+
 center, which is required to oxidize iron to a di-Fe
3+
, before conformational changes in the 
H130 side chain allow the Fe
3+
 to be translocated into the BfrB core, so instead, Fe2+ is oxidized 
outside of the protein. 
Molecular Simulations 
The molecular dynamics (MD) simulations performed on the D34F mutant showed that 
the mutant is less flexible than the wt protein.  The MD simulations show that the D34F mutant 
exhibits fluctuations in the long loops connect helices B and C and the N- and C- termini.  The 




flexibility in C- terminal half of helices D, and in the N-terminal half of helix C.  In Figure 4-8 it 
can be seen that the fluctuations seen in the wt protein are significantly greater than in the D34F 
mutant at all sites except the long loop connecting helices B and C.  The D34F mutation blocks 
the B-pore and packs against the L63 side chain, which disrupts the folding/unfolding transitions 
in the C-termini of helix D and the breathing motion of the B-pore.  The dampened motion from 
the hydrophobic packing limits the conformational freedom of F34 and F63 side chains to one 
rotamer.  The permeability of the B-pore becomes limited. 
The MD simulations also show how the ferroxidase activity was affected by the D34F 
mutation.  In the wt protein, the flexibility in the C-terminal half of helix D functions to couple 
breathing motions in the 4-fold and B-pores with the ferroxidase center ligands.  These motions 
help the movement of H130 to enable its gating motion, thus facilitating and translocation of the 
Fe
3+
 into the cavity.  In the D34F mutant, the flexibility of helix D is much lower and prevents 
the gating motion of the H130 side chain.  Hence, the results of the MD simulations confirm the 
insights from the crystal structure that the H130 side chain is “trapped” in the gate open 
confirmation (Figure 4-9).  The MD simulations show 3 rotamer states of H130 in Figure 4-9A 
for wt, but only one rotamer state for D34F mutant in Figure 4-9B. The changes in the rotameric 
states (x1, x2) for the D34 and F64 side chains in wt BfrB are seen in Figure 4-9C contribute to 
the breathing motion of the B-pore.  In comparison, the distribution of the rotameric states seen 





Figure 4-8: Molecular dynamics simulation of the fluctuations in wt and D34F BfrB.  The top 
row shows plots of per-residue backbone RMSF in system E2 (red), E10 (green), E40 (blue), and 
per-residue crystallographic B-factors (black); helices A-E are indicated as boxes, and 
ferroxidase center residues are highlighted in green. The middle row depicts the per-residue 
backbone RMSF (systems E2) mapped onto a BfrB subunit, and the bottom row shows per-
residue backbone RMSF mapped on six subunits of the 24-mer assembly to illustrate relative 
flexibility at the 4-fold (blue stars), 3-fold (green stars), and B-pores (red stars).  Flexibility 







Figure 4-9: Close up view of a B-pore taken during the MD simulations of (A) wt and (B) D34F 
BfrB. The three rotameric states of the F64 side chain in wt BfrB are depicted in white, yellow, 
and magenta sticks in (A), and the three rotameric states of D34 are indicated in the plot shown 
in (C). The rotameric exchange of D34 and F64 contributes to the breathing motions of the B-
pores as well as ion traffic across B-pores in wt BfrB. In the D34F structure packing of F34 
against L63 (spheres) likely contributes to the lower flexibility of B-pores in the mutant, due to  
only one conformational rotamer of the F34 side chain (D) and only one conformation of the F64 





The molecular dynamics simulations that suggested the B pores were the location of iron 
release[5] led to the D34F mutant being prepared as a way to study disruption of iron release 
from BfrB.  Although we could not study the effect on iron release because the mutant is not 
capable of storing iron, we used the D34F mutant to show that dynamic fluctuations of 
connecting the B-pores with the ferroxidase center are necessary to provide the gating motion of 
H130 at the ferroxidase, which is crucial for iron oxidation and uptake by BfrB. Using X-ray 
crystal structure and molecular dynamics simulations we were able to complement the results 
seen in the laboratory with the iron uptake experiments where D34F was able to only uptake 
about 24% of the Fe atoms compared to 85% seen in wt.   
The crystal structure showed that mutating the negatively charged D34 to the 
hydrophobic phenylalanine blocks the B-pores and decreases the hydrophilicity of the B-
channels, which allowed us to obtain a snapshot of Fe ions in the B-pores, where they are 
coordinated by D132 (Figure 4-6).  The flexibility of the ferroxidase center was affected and 
caused by the mutation and caused the H130 residue to remain in the gate open conformation 
(Figure 4-7).  The molecular dynamic simulations showed that F34 inhibited the fluctuations of 
the side chains that were necessary to make the conformational change at the ferroxidase center.  
F34 caused a decrease in the breathing motions of the B-pore because it packs against the L63 
side chain. This packing also affected the folding and unfolding transitions of the C-terminal 
portion of helix D which lowered its flexibility and the ability of H130 to undergo the 
conformational change (Figure 4-9). Hence, these results show that concerted motions involving 




the flexibility by introduction of the D34 F mutation impairs ferroxidase activity and iron 
mineralization in the BfrB core. The results also provide further insight into iron traffic through 
the B-pores in BfrB.   
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Chapter 5 : Inhibitors of the BfrB-Bfd Interaction Increase 
Susceptibility to Antibiotics 
Introduction 
Antibiotic resistance is becoming an increasing problem due to excessive amounts of 
antibiotics used for human therapy as well as animal farming [1].  The increasing exposure of 
antibiotics allows for more opportunities for bacteria to develop resistance.  Bacteria are capable 
of becoming resistant by coding genes that are resistant to a single drug, increasing expression of 
efflux pumps, which exports a wide range of drugs, and developing mutations to specific protein 
targets that would decrease the susceptibility to man-made compounds [1]. The development of 
resistance has become so extreme, in 2013 the CDC reported that approximately 23,000 deaths 
were caused by antibiotic resistant pathogens [2] and they developed a national strategy to 
combat antibiotic-resistant bacteria [3]. In this strategy they outlined 5 goals aimed at stopping 
and controlling the spread of antibiotic resistant pathogens. One of these goals is the 
development of new antibiotics [3]. In the past twenty years there have not been new classes of 
antibiotic developed, and the new antibiotics that have been released to the market target the 
same cellular processes as the old antibiotics [4]. This has led to the need to develop antibiotics 
that have different targets.  Research has been started to search for new targets, such as virulence 
factors, quorum sensing, fatty acid biosynthesis, and cell division [5-8], as well as targeting 





work being completed in our lab has been focusing on another new target, which is disrupting 
iron homeostasis by inhibiting the protein-protein interaction of the iron storage protein 
bacterioferritin B (BfrB) and the bacterioferritin-associated ferredoxin (Bfd) in Pseudomonas 
aeruginosa.  To develop compounds that can specifically bind BfrB at the Bfd-binding site, our 
lab has been utilizing concepts in fragment-based drug design (FBDD) and structure-based 
design. 
A library of 200 fragments, which are defined as molecules with molecular weights less 
than 300 Da, was screened by NMR to discover hits that bind to BfrB at the Bfd-binding site.  
Fragment hits were then used in co-crystallization trials with BfrB, and computational 
approaches were used to predict hits at the binding site.  A crystal structure of a fragment that 
bound to the Bfd binding spot on BfrB was obtained, which allowed us, in collaboration with Dr. 
Richard Bunce (Oklahoma State University), to grow and modify the compounds to increase 
binding affinity.  Knowing the structure of the BfrB-Bfd interaction site, we were capable of 
modifying the fragments to interact with the key residues at the binding site. To determine if the 
modified compounds were increasing affinity and specificity, several assays were performed: (i) 
The binding affinity of compounds for BfrB was measured using SPR or fluorescence 
polarization methods, (ii) the efficacy of compounds to inhibit iron release from recombinant 
BfrB was measured using an in vitro iron release assay developed in our laboratory, (iii) I 
investigated potential adjuvant effects of our compounds to enhance the bactericidal activity of 
existing antibiotics against Pseudomonas aeruginosa. This assay is important to determine if the 




test the efficacy of the compounds on P. aeruginosa, killing assays and growth curves were 
performed in the presence of the compound and/or antibiotics.   
P. aeruginosa is a gram-negative opportunistic pathogen that causes infections in 
immune compromised patients such as burn victims and cystic fibrosis patients [10].  It is also 
the most common multi-drug resistant gram-negative pathogen to cause pneumonia in 
hospitalized patients [11]. Many of the clinical isolates are resistant to antibiotics such as 
aminoglycosides and ciprofloxacin[11]; therefore the synergistic effect of our compounds with 
the antibiotics ciprofloxacin and the aminoglycoside tobramycin was tested.  I showed that 
compounds demonstrated by our laboratory to (i) engage the Bfd-binding site of BfrB, (ii) inhibit 
in vitro iron release from BfrB, potentiate the antibiotic activity of antibiotics.  For example, one 
compound was able to increase the killing of P.aeruginosa by 2 logs. The compounds have also 
shown to cause a slight delay in growth when added immediately after inoculation.  As the 
compounds are continued to be modified to increase binding affinity, the experiments to 
determine adjuvant effects with antibiotics will continue.  The results presented below provide 
promising progress towards the development of possible new antibiotics or adjuvants to current 
antibiotics, as well as probes that can be used to further investigate bacteria’s response to the 





Bacterial Strains and Media  
 The Pseudomonas aeruginosa strain PA01, purchased from the University of 
Washington, Manoil Lab and the strain PA14, obtained from the Chandler lab at the University 
of Kansas, were used.  The media used in killing curves was either M63 or Luria-bertani (LB).  
M63 was modified from O’Toole and Kolter [12]. M63 media is prepared by dissolving 2 g/L 
KH2PO4 (Sigma), 13.6 g (NH4)2SO4 (Sigma), 3 µM FeSO4-7H2O (Fisher) and 1 mM MgSO4 
(Fisher) per 1L water, and autoclaving.  Then 2 g glucose (Fisher), 5 g casamino acids (Fisher), 
0.25 g tryptophan (Sigma), 4 g citric acid (Sigma), are added, and the pH is adjusted to 7.0 with 
the addition of KOH and the solution is filter sterilized.  LB was prepared by weighing 25 g/L of 
dry, pre-made LB (Fisher), dissolving in 1 L of water and adjusting the pH to 7.0.  
Killing Assays 
 Single colonies were grown in 5 mL of M63 media at 230 rpm and 37 °C overnight.  The 
overnight inoculum was adjusted to 0.01 using a 1 cm cuvette.  191 µL of the diluted overnight 
culture was added to multiple wells in a 96 well plate.  The plate was wrapped with parafilm and 
placed in a shaker incubator for incubation at 200-210 rpm and 37 °C for 5 h (Final OD = 0.2-
0.3) to reach the beginning of the exponential growth phase.  Then 5 µL of antibiotic stock 
solution and/ or compound were added to the wells to the desired concentrations. DMSO was 
used as a control in Cipro treated only cultures. Before treatment of compound and Cipro as well 




removed by a pipette, serially diluted in PBS, and ten 10 μL drops would be plated on 
Pseudomonas Isolation Agar (PIA). The PIA plates would be incubated overnight at 37 °C for 
15- 18 h.  Single colonies would be counted and the colony forming unit/ mL (CFU/mL) would 
be determined.  All compounds were kept in stock solutions dissolved in 100% DMSO.  Care 
was taken to ensure that the volume of compound added kept the concentration of DMSO below 
3% to a final volume of 200 µL cultures.   
Antibiotic and Compound Stock Solutions 
Ciprofloxacin-HCl (MP Biomedicals) and Tobramycin (Fisher) were dissolved in 
autoclaved nanopure water, filter-sterilized with 0.2 µm filter syringe, and stored at -20 °C in 
sterile microcentrifuge tubes.  Ciprofloxacin stock solutions were prepared in a volumetric flask 
at 10 mg/mL and serially diluted to 20 or 40 µg/mL to be stored at -20 °C.  Tobramycin was 
prepared at 10 mg/mL and diluted to 2 or 5 mg/mL stock solutions that were stored at -20 °C.  
Storage of antibiotic stock solutions at -20 °C was for a maximum of 3 months before being 
discarded. Fresh frozen stock solutions were thawed and used only once for each assay. 
Growth Curves with Compound Only 
 Single colonies were grown in 5 mL of LB media at 230 rpm and 37 °C overnight.  The 
overnight inoculum was diluted in LB media to an optical density of 0.5, which was measured 
using 1 cm cuvettes (OD600 = 0.2 for 250 µL culture in Spectramax i3x plate reader). 245 µL of 
diluted overnight culture and 5 µL of stock compound solution in DMSO for a final volume of 




shaking plate reader, set to 37 °C, high orbital shaking every 15 minutes for 15-24 hours, and 
reading OD 600 nm every 30 minutes.   
Growth Curves with Cipro and Compound  
Single colonies were grown in 5 mL of LB media at 230 rpm and 37 °C overnight.  The 
overnight inoculum was diluted in LB media to an optical density of 0.05 using a 1 cm cuvette. 
235 µL of diluted overnight culture, 5 µL of stock compound solution in DMSO, and 10 μL of 
stock Cipro solution were added for a final volume of 250 µL culture per well in a 96 well plate.  
The 96- well plate was placed in the Spectramax i3x shaking plate reader set to 37 °C, high 
orbital shaking every 15 minutes for 15 hours, and reading OD 600 nm every 30 minutes.  After 
15 h of incubation, the entire content of the wells was suspended in 1 mL of sterile phosphate 
buffer saline (PBS) pH 7.4, and serially diluted in 10-fold increments.  Ten 10 µL drops from 
each of the dilutions were plated on PIA.  Drops were allowed to dry for 30-60 minutes, and then 
incubated at 37 °C for about 15-18 h.  Single colonies were counted and the CFU/mL was 
determined by multiplying the dilution factor by the number of colonies and divided by the 
volume plated. 
Results 
Compound FC996  
 After screening a library of fragments the most promising hits were tested by laboratory 
members (Dr. Huili Yao and Dr. Yan Wang) in order to determine the efficacy of compounds at 




and susceptibility.  To construct the killing curves, bacteria were grown in M63 media to the start 
of the exponential growth phase and then treated with antibiotics and/or compound.  Prior to 
treatment, an entire well was removed from the 96 well- plate, serially diluted in PBS, and plated 
on PIA.  The cell count obtained from this well served as the control before treatment.  After 
treatment, the cell culture was incubated for an additional 3 or 4 h and then the cell count was 
determined by serial dilutions and plating on PIA.  One of the fragments tested, labelled 
compound FC996, was shown by lab members to bind BfrB at the Bfd-binding site.  As can be 
seen in Figure 5-1, treatment of P. aeruginosa cells with a combination of compound 1 (1, 2, or 3 
mM) and ciprofloxacin (0.8 µg/mL), increased the killing of P. aeruginosa.  The increase in 
killing efficacy with compound FC996 is not yet substantial. The most likely reason is that the 
binding affinity of compound FC996 for BfrB is approximately 1.2 mM. This low binding 
affinity is typical of fragments. At this stage, the important observation is that the compound 
binds the target (BfrB) and elicits increases the killing efficacy of ciprofloxacin.  As will be 
shown below, as we improve the binding affinity of compounds by synthetic elaboration of 


























0.8g/mL Cipro + 1mM FC996
0.8g/mL Cipro + 2mM FC996
0.8g/mL Cipro + 3mM FC996
 
Figure 5-1:  Bacterial survival 3 h after treatment with compound FC996.  1, 2, and 3 mM 
compound was tested with 0.8 µg/mL of ciprofloxacin. After 3 hours of treatment, the bacterial 
survival treated with Cipro only (red) was 5%, with 1 mM compound plus cipro (green) 1%, 2 
mM compound + Cipro (blue) 0.5%, and 3 mM compound plus Cipro (purple) 0.1%. 
Compound BN-XVI-069  
As the compounds were elaborated synthetically, the binding affinity increased, as well 




It was shown by X-ray crystallography that 69 binds BfrB at the Bfd-binding spot. When this 
compound was used together with ciprofloxacin, the killing efficiency of the antibiotic was 
increased by 2 logs compared to treatment with Cipro only (Figure 5-2A).  An isomer of 69, 
compound BN-XVI-010 (10) did not show strong binding to BfrB and did not increase the 
killing efficacy of Cipro against P. aeruginosa cells (Figure 5-2B).  These observations indicate 
that binding of compounds to the Bfd-binding site on BfrB is important to increase the killing 
activity of ciprofloxacin.   
 To determine if compound 69 was going to help other families of antibiotics, it was tested 
with the aminoglycoside, Tobramycin.  P. aeruginosa cultures were grown to log phase and then 
treated with 50 µg/mL of Tobramycin and 200 or 400 µM compound 69 for 4 hours.  The 
addition of compound 69 caused an increase in killing compared to Tobramycin alone.  
Compound 69 also showed to be dose dependent by having a larger effect of killing with 400 µM 
compared to treatment with only 200 µM as seen in Figure 5-3.  Treating with Tobramycin does 
not kill the bacteria as fast as Cipro which is why the treatment was longer.  Also, the killing 
difference was not as large compared to Cipro, but there was still an effect.  This may suggest 
that the compounds will be more effective when used with fluoroquinolones compared to 
aminoglycosides, or it will take a compound that has higher binding affinity and is more stable to 
increase the killing to make it similar as the Cipro treated cultures.  Compound 69 was also 
shown to begin breaking down over time. This gave an explanation why after 3-4 hours it would 
reach a plateau of killing.  This led to modifying the structure again to increase the stability and 





Figure 5-2:  Comparison of the adjuvant properties of isomeric compounds.  (A) Cultures were 
grown in M63 media to mid-log phase and treated with 800 µM compound 69 plus Cipro or 1 
µg/mL Cipro only.  After 3 h of treatment with compound 69, which binds BfrB at the Bfd 
binding site, potentiates the killing activity of Cipro by 2 logs; treatment with 69 + Cipro (red 
bar), treatment with Cipro alone (black bar). (B) Compound 10 is an isomer of 69 but does not 





Figure 5-3: Bacterial survival 4 h after treatment with 50 µg/mL Tobramycin and Compound 69. 
The effect caused by the compound is dose dependent and increases killing in combination with 
Tobramycin. The treatment with Tobramycin only (black bar) resulted in 5% survival, 
Tobramycin + 200 µM 69 (red bar) 4% survival, and Tobramycin + 400 µM 69 (green bar) 1.5% 
survival. 
Compound GKK-008-057 
Compound GKK-008-057 (57) is another compound showing promising results regarding 
the potentiation of ciprofloxacin.  As seen in Figure 5-4, treatment with compound alone causes 




after the treatment of P. aeruginosa cells with 1 µg/mL ciprofloxacin alone results in about 10% 
survival.  In comparison, when cells are treated with Cipro (1 µg/mL) and compound, there is a 
clear dose dependent response, from 200 to 600 µM compound, which is the limit of solubility of 
the compound in aqueous solutions.  At concentrations near 600 µM the compound tends to 
precipitate, which may explain the increase in the standard deviations at this concentration. 
The effect of compound 57 on cell growth was studied by adding it at the beginning of a culture 
in LB media. LB media was used instead of M63 because M63 has been reported to induce the 
formation of microcolonies [12] which we suspected would disrupt an accurate reading of the 
OD600.  Figure 5-5 shows results obtained from incubating P. aeruginosa cells in the presence of 
compound 57.  The presence of compound causes a slight delay in initial growth but the cell 
density, as judged by OD600, is lower in the treated cultures. The higher the concentration of 57 
added, the lower the cell density.  
P. aeruginosa growth was also tested in the presence of Cipro concentrations below and 
close to the minimum inhibitory concentration (MIC) of the antibiotic. Cipro and compound 57 
were both added immediately after inoculation in LB media.  The cells were grown for 15 hours 
at 37 °C, and cell growth was monitored by measuring the OD600 at 30 min intervals in a shaking 
plate reader (Figure 5-6C).  At 15 h the cultures were serially diluted and plated to enumerate the 
viable cells, log CFU/mL (Figure 5-6A, 5-6B).  Note that by keeping the concentration of Cipro 
constant (0.2 μg/mL), treatment with a combination of Cipro and increasing concentrations of 57 
results in a decrease of viable bacterial cells. There is about a 2 log difference in cell viability 




0.2 µg/mL Cipro and 400 µM 57.  Hence, the treatment of P. aeruginosa cultures with the 
compound affects the growth of the cells as well as enhances the efficacy of Cipro. 
The compounds were also tested in the presence of the P. aeruginosa strain PA14.  PA14 
has the bfrB and bfd genes, so it was of interest to determine if the compounds would have a 
similar effect. Figure 5-7 shows that the final cell density (OD600) is lower as the concentration 
of 57 increases, observations that are similar to those described above with P. aeruginosa PAO1.  
This suggest that 57 exerts a dose dependent growth delay of the bacteria indicating that the 
compounds being developed in the lab could be used not only against P. aeruginosa PA01, but 
also other P. aeruginosa strains, and perhaps other pathogens where the bfr and bfd genes show 





Figure 5-4:  Bacterial survival 3 h after treatment with compound 57 and 1 µg/mL Cipro. 
Treating mid-log phase cultures with only 57 at 200 µM (red bar) shows minimal differences 
compared to untreated (2% DMSO) cultures (black bar).  Treatment of mid-log phase cultures 
with 1 µg/mL Cipro only results in approximately 10% survival.  Treatment of mid-log phase 
cultures with a combination of Cipro (1 µg/mL) and compound 57 shows that cell survival is 





Figure 5-5:  P. aeruginosa PAO1 growth curves in the presence of 50, 100, 200, 300, and 400 
µM 57 or untreated (2% DMSO).  The final cell density is lower as the concentration of 57 is 
increased.  The presence of 57 at all concentrations slows the log phase growth compared to 





Figure 5-6:  Growth in the presence of 0.2 µg/mL Cipro and compound 57. (A) After incubating 
for 15 h, cultures were diluted in PBS and plated on PIA. Plating at the same dilution factor 
shows that the number of viable cells decreases with increasing concentration of compound: (1) 
0.2 µg/mL Cipro only, (2) 0.2 µg/mL Cipro + 50 µM 57, (3) 0.2 µg/mL Cipro + 100 µM 57, (4) 
0.2 µg/mL Cipro + 200 µM 57, (5) 0.2 µg/mL Cipro + 300 µM 57, (5) 0.2 µg/mL Cipro + 400 
µM 57.  (B) Log CFU/mL counts of cell viability from 15 h cultures corroborate the effects of 
treatment with 0.2 µg/mL and increasing concentrations of 57. (C) Growth curve of P. 
aeruginosa in the presence of 0.2 µg/mL Cipro with 2% DMSO and 0.2 µg/mL Cipro in addition 





Figure 5-7:  Growth curves of PA14 in the presence of compound 57 only. As the concentration 
of the compound increases, there is a slight delay in the log phase and the final OD600.  This 
suggests that the compounds could be promising for other strains of bacteria that have the BfrB 
and Bfd proteins. 
Discussion 
 The synthetic evolution of the fragment hits has allowed improvement of compound 
binding affinity (Kd from 1,200 μM to 10 μM). The increases in binding affinity have been 
accompanied with concomitant increases in ciprofloxacin adjuvant activity against P. aeruginosa 
PAO1. In this context, fragments, which showed the lowest binding affinity, also showed modest 
adjuvant activity, increasing the killing activity of Cipro by less than a log at 5 mM. In contrast, 
compounds that bind BfrB with approximately 10 μM Kd exhibit enhanced killing activity of 




have a larger killing effect when added with ciprofloxacin, but they also increase the cell’s 
susceptibility to tobramycin also.  Increasing the susceptibility to commonly used antibiotics 
could be a possible solution to rescue antibiotics for which bacteria have already developed 
resistance.  To test this idea, future work will test the effect of the compounds we are developing 
against clinical isolates of P. aeruginosa with demonstrated ciprofloxacin resistance.  
When compounds that hit BfrB on the Bfd binding site are added alone during mid-log 
phase it does not decrease the cell count significantly, but it does slow down the growth when it 
is added immediately after inoculation as seen in Figure 5-5.  In addition when compound 57 and 
Cipro are added at the beginning of growth, it has shown up to 2 logs lower cell count with 400 
µM of 57.  The effect of the compounds on the cell is not completely understood, but the Rivera 
group is working to test a hypothesis that sudden inhibition of iron mobilization from BfrB, 
caused by blocking the BfrB:Bfd interaction with the compound, causes a sudden disruption of 
iron homeostasis.  We suspect this would prevent efficient incorporation of Fe into iron utilizing 
enzymes, such as those in the TCA cycle, thus rendering the bacterial cell less fit to combat the 
deleterious effects caused by antibiotic treatment. 
Compound 57 has also shown to lower the final cell count in the presence of 
P.aeruginosa PA14 which suggests the compounds could be used to treat several strains of P. 
aeruginosa and perhaps other pathogens that have the same residues at the BfrB-Bfd interaction 
site.   
The use of the compounds will not only be significant in their adjuvant effects to 
antibiotics, but they will also act as excellent probes to study bacterial iron homeostasis.  Mutant 




compounds that inhibit the BfrB:Bfd interaction can cause immediate disruption of iron 
homeostasis (see Chapter 3), to which bacteria can’t adapt immediately. Hence, studying the 
effects caused by compound treatment will likely provide new insights into our understanding of 
bacterial iron homeostasis. Future analysis of the transcriptomics and phenotypes of the cells 
treated with compound could provide insight to the many unanswered questions of iron 
homeostasis.  In this context, it is important to underscore that antibiotics have not only been 
used to treat infections, but they have also been used to further understand how bacteria function 
[14, 15].  Hopefully, the inhibitors of the BfrB-Bfd interaction can do the same for iron 
homeostasis in multiple pathogens.  
 At the time of this publication work is still ongoing to increase the binding affinity of the 
compounds and their effect on iron release in vitro and their adjuvant effect with antibiotics in P. 
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